

PATHEON INC  
 Form 10-Q  
 September 05, 2013  
Table of Contents

UNITED STATES  
 SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

---

FORM 10-Q

---

**S** QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2013

OR

**£** TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 000-54283

---

PATHEON INC.

(Exact name of registrant as specified in its charter)

---

Canada

(State or other jurisdiction of incorporation or organization)

Not Applicable  
 (I.R.S. Employer Identification No.)

c/o Patheon Pharmaceuticals Services Inc.

4721 Emperor Boulevard, Suite 200

Durham, NC

(Address of principal executive offices)

919-226-3200

(Registrant's telephone number, including area code)

27703

(Zip Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes **S** No **£**

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes **S** No **£**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer **£** Accelerated filer **S**

Non-accelerated filer **£** (Do not check if a smaller reporting company) Smaller reporting company **£**

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes **£** No **S**

As of August 30, 2013, the registrant had 140,928,525 restricted voting shares outstanding.



Table of Contents

Patheon Inc.

## TABLE OF CONTENTS

PART I - Financial Information	
Item 1.	<u>Financial Statements</u>
	<u>Unaudited Consolidated Balance Sheets as of July 31, 2013 and October 31, 2012</u> 1
	<u>Unaudited Consolidated Statements of Operations for the Three and Nine Months Ended July 31, 2013 and 2012</u> 2
	Unaudited Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended July 31, 2013 and 2012 2
	Unaudited Consolidated Statement of Changes in Shareholders' Equity for the Nine Months Ended July 31, 2013 4
	<u>Unaudited Consolidated Statements of Cash Flows for the Nine Months Ended July 31, 2013 and 2012</u> 5
	<u>Notes to Unaudited Consolidated Financial Statements</u> 6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations 28
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 46
Item 4.	<u>Controls and Procedures</u> 47
PART II - <u>Other Information</u> 48	
Item 1.	<u>Legal Proceedings</u> 48
Item 1A.	<u>Risk Factors</u> 48
Item 6.	<u>Exhibits</u> 48
	<u>Signatures</u> 49
	<u>Exhibit Index</u> 50

---

Table of Contents

## Item 1. Financial Statements

Patheon Inc.  
CONSOLIDATED BALANCE SHEETS  
(unaudited)

	As of July 31, 2013	As of October 31, 2012
(in millions of U.S. dollars)	\$	\$
Assets		
Current		
Cash and cash equivalents	40.9	39.4
Accounts receivable	181.7	161.7
Inventories	144.3	82.3
Income taxes receivable	21.0	0.4
Prepaid expenses and other	21.7	11.9
Deferred tax assets - short-term	6.6	4.3
Total current assets	416.2	300.0
Capital assets	492.2	416.4
Intangible assets	70.6	—
Deferred financing costs	21.0	4.9
Goodwill	45.3	3.5
Investments	8.5	6.3
Other long-term assets	17.3	11.8
Total assets	1,071.1	742.9
Liabilities and shareholders' equity		
Current		
Short-term borrowings	5.2	2.4
Accounts payable and accrued liabilities	205.7	186.2
Income taxes payable	2.2	5.7
Deferred revenues - short-term	14.8	13.9
Deferred tax liabilities - short-term	0.3	—
Current portion of long-term debt	6.8	—
Total current liabilities	235.0	208.2
Long-term debt	598.4	310.7
Deferred revenues	21.8	28.9
Deferred tax liabilities	57.4	23.0
Other long-term liabilities	44.6	47.8
Total liabilities	957.2	618.6
Shareholders' equity		
Restricted voting shares	610.5	572.5
Contributed surplus	15.9	16.5
Accumulated deficit	(525.5)	(478.6)
Accumulated other comprehensive income	13.0	13.9
Total shareholders' equity	113.9	124.3
Total liabilities and shareholders' equity	1,071.1	742.9
see accompanying notes		



Table of Contents

Patheon Inc.

## CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
(in millions of U.S. dollars, except per share information)	\$	\$	\$	\$
Revenues	265.7	203.7	733.1	539.1
Cost of goods sold	194.6	148.2	562.6	435.2
Gross profit	71.1	55.5	170.5	103.9
Selling, general and administrative expenses	44.8	29.9	121.6	99.0
Research and development	2.8	—	7.4	—
Repositioning expenses	4.5	0.1	11.0	6.9
Acquisition and integration costs	1.2	—	9.3	—
Impairment charge	1.2	—	11.3	57.9
Gain on sale of capital assets	—	—	(1.6	) —
Operating income (loss)	16.6	25.5	11.5	(59.9 )
Interest expense, net	12.6	6.8	35.0	19.8
Foreign exchange loss, net	—	0.4	1.5	0.6
Refinancing expenses	—	—	29.2	—
Other income, net	(1.2 )	(0.5 )	(1.8 )	(0.6 )
Income (loss) from continuing operations before income taxes	5.2	18.8	(52.4 )	(79.7 )
Provision for (benefit from) income taxes	0.9	3.3	(5.5 )	3.6
Income (loss) from continuing operations	4.3	15.5	(46.9 )	(83.3 )
Loss from discontinued operations	—	—	—	(0.2 )
Net income (loss) attributable to restricted voting shareholders	4.3	15.5	(46.9 )	(83.5 )
Basic income (loss) per share				
From continuing operations	\$0.031	\$0.120	(\$0.337 )	(\$0.643 )
From discontinued operations	—	—	—	(\$0.002 )
Net income (loss) per share, basic	\$0.031	\$0.120	(\$0.337 )	(\$0.645 )
Diluted income (loss) per share				
From continuing operations	\$0.030	\$0.120	(\$0.337 )	(\$0.643 )
From discontinued operations	—	—	—	(\$0.002 )
Net income (loss) per share, diluted	\$0.030	\$0.120	(\$0.337 )	(\$0.645 )
Weighted-average number of shares outstanding (in thousands)				
Basic	140,640	129,639	139,232	129,639
Diluted	145,694	129,692	139,232	129,639
see accompanying notes				

Table of Contents

Patheon Inc.

## CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(unaudited)

(in millions of U.S. dollars)	Three months ended July		Nine months ended July	
	31, 2013	2012	31, 2013	2012
	\$	\$	\$	\$
Net income (loss) attributable to restricted voting shareholders	4.3	15.5	(46.9	) (83.5
Other comprehensive income (losses), net of income taxes				
Change in foreign currency (losses) gains on investments in subsidiaries, net of hedging activities	(1.9	) (13.6	) 2.4	(20.5
Change in value of derivatives designated as foreign currency cash flow hedges	(2.3	) (0.7	) (3.2	) 1.2
(Losses) gains on foreign currency cash flow hedges reclassified to consolidated statements of loss	(0.2	) 0.5	(1.0	) 0.6
Net change in pension liability	0.3	—	0.9	0.3
Curtailed impact and plan asset remeasurement, net of tax	—	—	—	6.0
Comprehensive income (loss) attributable to restricted voting shareholders	0.2	1.7	(47.8	) (95.9
see accompanying notes				

Table of Contents

Patheon Inc.

## CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

(unaudited)

(in millions of U.S. dollars)	Restricted Voting Shares	Contributed Surplus	Accumulated Deficit	Accumulated Other Comprehensive Income	Total Shareholders' Equity
Balance at October 31, 2012	\$572.5	\$16.5	\$ (478.6 )	\$ 13.9	\$ 124.3
Proceeds from equity offering, net	29.2	—	—	—	29.2
Stock options exercised	8.8	(3.0 )	—	—	5.8
Stock-based compensation	—	2.4	—	—	2.4
Comprehensive income (loss):					
Net loss attributable to restricted voting shareholders	—	—	(46.9 )	—	(46.9 )
Change in foreign currency gains on investments in subsidiaries, net of hedging activities	—	—	—	2.4	2.4
Change in value of derivatives designated as foreign currency cash flow hedges	—	—	—	(3.2 )	(3.2 )
Losses on foreign currency hedges reclassified to consolidated statement of operations	—	—	—	(1.0 )	(1.0 )
Net change in pension liability	—	—	—	0.9	0.9
Subtotal	—	—	(46.9 )	(0.9 )	(47.8 )
Balance at July 31, 2013 see accompanying notes	\$610.5	\$15.9	\$ (525.5 )	\$ 13.0	\$ 113.9



Table of Contents

Patheon Inc.

## CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	Nine months ended July	
	31,	
	2013	2012
(in millions of U.S. dollars)	\$	\$
Operating activities		
Loss from continuing operations	(46.9	) (83.3
Adjustments to reconcile loss from continuing operations to cash (used in) provided by operating activities		
Depreciation and amortization	35.6	30.8
Impairment charge	11.3	57.9
Foreign exchange loss on debt	0.4	—
Other non-cash interest	8.2	0.9
Change in other long-term assets and liabilities	(10.7	) (1.7
Deferred income taxes	0.9	(0.3
Amortization of deferred revenues	(13.5	) (7.6
Gain on sale of capital assets	(1.6	) —
Stock-based compensation expense	2.4	2.5
Other	(1.7	) (0.8
	(15.6	) (1.6
Net change in non-cash working capital balances related to continuing operations	(22.3	) (9.9
Increase in deferred revenues	12.3	18.7
Cash (used in) provided by operating activities of continuing operations	(25.6	) 7.2
Cash used in operating activities of discontinued operations	(0.1	) (0.4
Cash (used in) provided by operating activities	(25.7	) 6.8
Investing activities		
Additions to capital assets	(34.2	) (32.9
Proceeds on sale of capital assets	6.6	0.1
Acquisitions, net of cash acquired	(256.1	) —
Cash used in investing activities of continuing operations	(283.7	) (32.8
Cash provided by investing activities of discontinued operations	—	0.1
Cash used in investing activities	(283.7	) (32.7
Financing activities		
Decrease in short-term borrowings	—	(1.3
Proceeds from long-term borrowings	633.8	35.5
Increase in deferred financing costs	(22.7	) —
Repayment of debt, net of penalty payment	(337.8	) (3.9
Share issuance costs	(0.8	) —
Proceeds on issuance of restricted voting shares	35.8	—
Cash provided by financing activities	308.3	30.3
Effect of exchange rate changes on cash and cash equivalents	2.6	(2.4
Net increase in cash and cash equivalents during the period	1.5	2.0
Cash and cash equivalents, beginning of period	39.4	33.4
Cash and cash equivalents, end of period	40.9	35.4
see accompanying notes		



Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared by Patheon Inc. (the "Company" or "Patheon") in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). Operating results for the three and nine months ended July 31, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending October 31, 2013 ("fiscal 2013"). These consolidated financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and therefore should be read in conjunction with the audited consolidated financial statements and notes for the fiscal year ended October 31, 2012 ("fiscal 2012") contained in the Company's Annual Report on Form 10-K for the year then ended. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect: the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and the reported amounts of revenue and expenses in the reporting period. Management believes that the estimates and assumptions used in preparing its consolidated financial statements are reasonable and prudent, however, actual results could differ from those estimates.

Changes in significant accounting policies

In connection with the Banner Acquisition (described in Note 2), the following accounting policies became more significant to the Company:

Revenue recognition on product sales

The Company now manufactures and sells proprietary products. With respect to the sales of these products, the Company recognizes revenue when title has transferred to the customer and the customer has assumed the risks and rewards of ownership. The Company also has agreements with various distributors that allow the Company to share in product profits. The Company recognizes these profits once the distributor ships the product and title passes to the distributor's customer. The Company does not offer return policies to its customers except for defective products.

Goodwill

As a result of the Banner Acquisition, the Company recorded goodwill representing the excess of the purchase price over the fair value of the assets acquired and the liabilities assumed. The Company tests goodwill for impairment at least annually in the fiscal fourth quarter, or when indications of potential impairment exist. The Company monitors for the existence of potential impairment indicators throughout the fiscal year. Testing is performed with respect to each of the Company's reporting units that have been allocated goodwill, which the Company has determined are the sites within its CMO segment.

If the Company's qualitative assessment reveals that goodwill impairment is more likely than not, the Company performs the two-step impairment test. Alternatively, the Company may bypass the qualitative test and initiate goodwill impairment testing with the first step of the two-step goodwill impairment test.

During the first step of the goodwill impairment test, the Company compares the fair value of the reporting unit to its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, then the Company concludes that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to measure possible goodwill impairment loss. During the second step, the Company hypothetically values the reporting unit's tangible and intangible assets and liabilities as if the reporting unit had been acquired in a business combination. The Company then compares the implied fair value of the reporting unit's goodwill to the carrying value of its goodwill. If the carrying value of the reporting unit's goodwill exceeds the implied fair value of the goodwill, the Company recognizes an impairment loss in an amount equal to the excess, not to exceed the carrying value of the reporting unit's goodwill. Once an impairment loss is recognized, the adjusted carrying value of the goodwill becomes the new accounting basis of the goodwill for the reporting unit.

## Intangible Assets

As a result of the Banner Acquisition, the Company has recorded various intangible assets, including technology, in process research and development, customer relationships and trade names. The Company tests for impairment of definite lived intangible assets whenever events or changes in circumstances indicate that the carrying amount will not be recoverable.

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

If such indicators are present, the Company assesses the recoverability of the intangible assets by determining whether the carrying value of such assets can be recovered through undiscounted future cash flows. If the sum of the undiscounted cash flows is less than the carrying amount, the excess of the carrying amount over the estimated fair value, based on the discounted cash flows, is recorded as a charge to earnings.

For indefinite-lived intangible assets other than goodwill, the Company compares the fair value of the intangible asset with the asset's carrying amount. If the fair value is less than the carrying amount, the Company recognizes an impairment. This impairment test for indefinite-lived intangible assets other than goodwill is conducted annually, concurrently with the goodwill impairment test.

Research and development expenses

The Company now has research and development costs that are expensed as incurred. These expenses relate to proprietary research and development efforts and consist of salaries and benefits, supplies and other costs.

Recently adopted accounting pronouncements

Effective November 1, 2012, the Company adopted Accounting Standards Update ("ASU") 2011-08, "Intangibles-Goodwill and Other (Topic 350): Testing Goodwill for Impairment" ("ASU 2011-08"), which amends U.S. GAAP Accounting Standards Codification ("ASC") 350, "Intangible Assets-Goodwill and Other." Under ASU 2011-08, an entity may elect the option to assess qualitative factors to determine whether it is necessary to perform the first step in the two-step impairment testing process. This guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's financial statements.

Effective November 1, 2012, the Company adopted ASU 2012-02, "Testing Indefinite-Lived Intangible Assets for Impairment" ("ASU 2012-02"). ASU 2012-02, was promulgated to reduce the cost and complexity of testing indefinite-lived intangible assets other than goodwill for impairment. ASU 2012-02 is intended to simplify indefinite-lived intangible impairment testing by allowing an entity to first assess qualitative factors to determine whether it is "more likely than not" that the fair value of an asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's financial statements.

Effective November 1, 2012, the Company adopted ASU 2011-05, "Comprehensive Income (Topic 220): Presentation of Comprehensive Income in U.S. GAAP" ("ASU 2011-05"). ASU 2011-05 requires that comprehensive income and the related components of net income and of other comprehensive income be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 also requires reclassification adjustments from other comprehensive income to net income be presented on the face of the financial statements. The amendments are effective for annual reporting periods beginning on or after December 15, 2011, and interim periods within those annual periods. However, in December 2011, the Financial Accounting Standards Board ("FASB") issued ASU 2011-12, "Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05" to defer the requirement to present reclassification adjustments from other comprehensive income on the face of the financial statements and allow entities to continue to report reclassifications out of accumulated other comprehensive income consistent with the requirements in effect before ASU 2011-05. Other than a change in presentation, the adoption of this guidance did not have a material impact on the Company's consolidated financial statements.

Recently issued accounting pronouncements

In July 2013, the FASB issued ASU 2013-11, “Income Taxes, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 states that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the

7

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013, with early adoption permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

In July 2013, the FASB issued ASU 2013-10, "Derivatives and Hedging, Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes" ("ASU No. 2013-10"). ASU 2013-10 permits the Fed Funds Effective Swap Rate (OIS) to be used as a U.S. benchmark interest rate for hedge accounting purposes, in addition to UST and LIBOR. The amendments also remove the restriction on using different benchmark rates for similar hedges. Prior to the amendments in this ASU, only U.S. Treasury and the LIBOR swap rates were considered benchmark interest rates. Including the Fed Funds Effective Swap Rate (OIS) as an acceptable U.S. benchmark interest rate in addition to U.S. Treasury and LIBOR rates provides a more comprehensive spectrum of interest rates to be utilized as the designated benchmark interest rate risk component under the hedge accounting guidance. The amendments in ASU 2013-10 are effective prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

In March 2013, the FASB issued ASU 2013-05, "Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity" ("ASU 2013-05"). ASU 2013-05 resolves the diversity in practice concerning the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets within a foreign entity. The guidance is effective for fiscal years and interim reporting periods within those fiscal years beginning after December 15, 2013. The amendments described in the ASU are to be applied prospectively to derecognition events occurring after the effective date; prior periods are not to be adjusted. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

In February 2013, the FASB issued ASU 2013-04, "Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date" ("ASU 2013-04"). ASU 2013-04 provides guidance for the recognition, measurement and disclosure resulting from joint and several liability arrangements. Examples of obligations that fall within the scope of the ASU include certain debt arrangements, other contractual obligations and settled litigation. The new guidance is effective on a retrospective basis for fiscal years and interim periods within those fiscal years beginning after December 15, 2013. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

In February 2013, the FASB issued ASU 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income" ("ASU 2013-02"). ASU 2013-02 requires enhanced disclosures about items reclassified out of accumulated other comprehensive income ("AOCI"). For items reclassified to net income in their entirety, the ASU requires information about the effect of significant reclassification items to appear on separate line items of net income. For those items where direct reclassification to net income is not required, companies must provide cross-references to other disclosures that provide details about the effects of the reclassification out of AOCI. Expanded disclosures concerning current period changes in AOCI balances are also required for each component of other comprehensive income on the face of the financial statements or in the notes. ASU 2013-02 is effective

prospectively for fiscal years beginning after December 15, 2012, and interim periods within those fiscal years. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

In December 2011, the FASB issued ASU 2011-11, "Disclosures about Offsetting Assets and Liabilities," which requires enhanced disclosures about financial instruments and derivative instruments that are either (i) offset in accordance with either Section 210-20-45 or 815-10-45 or (ii) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. The amendments are effective for annual reporting periods beginning on or after January 1, 2013 and interim periods within those annual periods. The amendments are required to be applied retrospectively for all prior periods presented. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.



Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

## 2. BANNER ACQUISITION

## Background

On December 14, 2012, the Company completed the acquisition of all of the issued and outstanding shares of capital stock of Sobel USA Inc., a Delaware corporation, and Banner Pharmacaps Europe B.V., a private limited company organized under the laws of The Netherlands (collectively "Banner") from Sobel Best N.V. and VION Holding, N.V., each corporation is organized under the laws of The Netherlands, for a net aggregate purchase price of approximately \$269.0 million (the "Banner Acquisition"). Banner is a pharmaceutical business focused on delivering proprietary softgel formulations, with four manufacturing facilities and a number of proprietary technologies and products.

## Purchase price allocation

The Banner Acquisition is accounted for using the acquisition method of accounting in accordance with ASC Subtopic 805-10, "Business Combinations," and the fair value concepts set forth in ASC Subtopic 820-10, "Fair Value Measurements and Disclosures". Under ASC 805-10, the total purchase price for Banner was allocated to the assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The allocation of the purchase price is based on estimates and assumptions that are subject to change within the measurement period. The excess of the purchase price over the fair values of the assets acquired and liabilities assumed was recorded as goodwill. Goodwill largely consists of geographic expansion of product sales, manufacturing and other synergies of the combined companies, and the value of the assembled workforce.

The estimated purchase price allocation for the Banner Acquisition is as follows:

	\$	
Cash and cash equivalents	12.7	
Accounts receivable	53.4	
Inventories	53.7	
Income taxes receivable	4.3	
Prepaid expenses and other	3.6	
Deferred tax assets-short-term	1.7	
Capital assets	91.0	
Intangible assets	75.1	
Goodwill	41.9	
Deferred tax assets - long-term	0.1	
Other long-term assets	0.3	
Accounts payable and accrued liabilities	(32.6	)
Deferred tax liabilities - short-term	(0.4	)
Other long-term liabilities	(3.5	)
Deferred tax liabilities-long-term	(32.3	)
Total purchase price	269.0	

The Company recorded all of the \$41.9 million of goodwill to its CMO segment. In addition, the Company does not expect any of the goodwill to be tax deductible.

## Valuations of intangible assets acquired

The weighted-average life of the acquired intangible assets is approximately 11.0 years. The following table sets forth the components of the acquired intangible assets by type:

9

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	Estimated Fair Value	Estimated Useful Life (in years)
	\$	
Trade names	0.8	5-6
Technology	46.4	10-12
Customer relationships	11.1	7-12
In-process research and development <sup>(1)</sup>	16.8	Indefinite
Total	75.1	

<sup>(1)</sup> In process research and development is currently classified as indefinite-lived intangible assets and will either begin to be amortized upon product approvals or written-off if not approved.

## Purchase price allocation and pre-acquisition adjustments

The Company continues to evaluate pre-acquisition contingencies, working capital and tax balances including deferred tax assets and liabilities relating to Banner that existed as of the acquisition date. If the Company makes changes to the amounts recorded or identifies additional pre-acquisition contingencies during the remainder of the measurement period, such amounts recorded will be included as an adjustment to the purchase price allocation during the measurement period.

## Financial results of the acquired business

The revenues and net loss of Banner for the period from December 15, 2012 through July 31, 2013 included in the consolidated statement of operations are as follows:

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
	\$	\$	\$	\$
Revenues	66.4	—	144.2	—
Loss from continuing operations	(13.3	) —	(42.9	) —

## Pro forma financial information

The following table presents pro forma results of operations and gives effect to the Banner Acquisition as if the transaction had been consummated on November 1, 2011. This unaudited pro forma financial information is provided for informational purposes only and is not necessarily indicative of what the actual results of operations would have been had the transactions taken place on November 1, 2011, nor is it indicative of the future consolidated results of operations or financial position of the combined companies.

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
	\$	\$	\$	\$
Revenues	265.7	269.1	766.7	738.5
Income (loss) from continuing operations	5.4	10.8	(21.3	) (91.8
Income (loss) per share from continuing operations, basic	\$0.038	\$0.083	\$(0.153	) \$(0.708
Income (loss) per share from continuing operations, diluted	\$0.037	\$0.083	\$(0.153	) \$(0.708

The unaudited pro forma financial information was prepared using the acquisition method of accounting and is based on the historical financial information of the Company and Banner, reflecting the Company's and Banner's combined

results of operations for the three and nine month periods ended July 31, 2013 and 2012. The historical financial information has been adjusted to give effect to the pro forma events that are (i) directly attributable to the Banner Acquisition, (ii) factually supportable and (iii) expected to have a continuing impact on the combined results of the Company and Banner. The unaudited pro forma consolidated results reflect primarily the following pro forma adjustments:

- additional interest expense and related refinancing costs related to the long-term debt used to fund the acquisition;
- additional amortization expense related to the fair-value of identifiable intangible assets acquired;

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

• additional cost of goods sold resulting from an increase in the fair value of acquired inventory and an increase in depreciation expense relating to the fair values of acquired property and equipment; and  
• removal of acquisition-related costs.

### 3. DISCONTINUED OPERATIONS, PLANT CONSOLIDATIONS, SALES AND ASSET IMPAIRMENTS Puerto Rico

The Company previously announced its plan to consolidate its Puerto Rico operations into its manufacturing site located in Manati and sell its plant in Caguas and that additional time was required to transition manufacturing operations from Caguas to Manati due to longer than expected customer regulatory time lines and increased product demand. The Company now estimates the total project repositioning expenses to be \$13.7 million, of which an additional \$0.4 million was recorded in the nine months ended July 31, 2013. Because the business in the Caguas facility is being transferred within the existing site network, its results of operations are included in continuing operations in the consolidated financial statements.

As previously announced, on February 28, 2013, the Company entered into a sale-leaseback agreement for the Caguas facility for \$7.0 million. The lease agreement is a month to month tenancy with a target, non-binding, termination date of December 31, 2013. The Company has the option to holdover the lease in the event further time is necessary to complete the transfer out of Caguas to Manati. In the event of a holdover, the term may be extended on a month to month basis. As a result of the sale leaseback, the Company recorded a prepaid rent asset for \$1.5 million during the second quarter, which it began amortizing immediately. A gain of \$1.1 million was recognized upon the sale.

The results of discontinued operations for the Company's Carolina facility (which the Company closed effective January 31, 2009) for the three and nine months ended July 31, 2013 and 2012 are as follows:

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
	\$	\$	\$	\$
Revenues	—	—	—	—
Cost of goods sold	—	—	—	—
Gross loss	—	—	—	—
Selling, general and administrative expenses	—	—	—	0.3
Gain on sale of capital assets	—	—	—	(0.1)
Operating loss	—	—	—	(0.2)
Loss before income taxes	—	—	—	(0.2)
Net loss for the period	—	—	—	(0.2)

On February 17, 2012, the Company finalized the sale of its Carolina, Puerto Rico facility for a nominal amount.  
Canada

Subsequent to the closing of the Banner Acquisition, the Company performed a review of Banner's facilities and decided to close the Olds, Canada facility by October 31, 2013. As a result of this decision, the Company conducted an impairment analysis on the long-term assets at this facility. Based on this analysis, which is discussed more fully below, the Company concluded that a non-cash impairment charge of \$10.0 million was required to reduce the carrying value of the long-term assets to their fair value and that a non-cash impairment charge of \$0.1 million was required to reduce the carrying value of the goodwill allocated to the Olds, Canada reporting unit to its fair value. The impairment charges reduced assets in the CMO segment by a total of \$10.1 million. The carrying value of this

property was reduced to its estimated fair value of \$4.9 million, which represents the salvage value of the building and land, less costs to sell, that was determined based upon an appraisal value (Level 2 valuation inputs). These facility assets will remain as held and used until a plan of sale has been initiated and the site is in a condition for immediate sale.

To determine whether any impairment charge was required with respect to the long-term assets at the Olds, Canada Facility, the Company performed a cash flow analysis over the remaining useful life of these assets, which following the

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

decision to close the facility was nine months. Because the expected operating cash flows were less than the carrying value of the assets, an impairment analysis was completed to calculate the amount of the impairment loss. Following this analysis, the Company reduced the book value of the site's long-term assets to the fair value of the facility, the book value of any assets that will be transferred to other sites and a minimal amount of value for residual equipment to be sold on the used equipment market.

Following the completion of the impairment analysis for the long-term assets at the Olds, Canada facility, the Company evaluated whether the goodwill allocated to the Olds, Canada reporting unit was impaired. The Company bypassed the qualitative assessment of whether it was more likely than not that goodwill was impaired, and performed the two-step impairment test. Because the reporting unit's carrying value is being reduced to net working capital plus the salvage value of the property, plant and equipment, the Company determined that there was no remaining value for the goodwill and thus it was fully impaired. The net amount required to be booked for the impairment of goodwill in the first quarter of fiscal 2013 was \$0.1 million.

#### 4. SUPPLEMENTAL BALANCE SHEET INFORMATION

##### Inventories

Inventories consisted of the following as of July 31, 2013 and October 31, 2012:

	July 31, 2013	October 31, 2012
	\$	\$
Raw materials, packaging components and spare parts	79.6	47.9
Work-in-process	45.0	34.4
Finished goods	19.7	—
Balance, end of period	144.3	82.3

##### Accounts payable and accrued liabilities

The following is the breakdown of accounts payable and accrued liabilities:

	July 31, 2013	October 31, 2012
	\$	\$
Trade payables	116.6	101.2
Interest payable	1.8	1.0
Accrued salaries and related expenses	50.3	51.4
Customer deposits	17.3	16.4
Other accruals	19.7	16.2
Balance, end of period	205.7	186.2

##### Intangible assets

As part of the Banner Acquisition, the Company obtained intangible assets. The following table summarizes gross carrying amounts and accumulated amortization related to the Company's identifiable intangible assets as of July 31, 2013:





Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	Gross carrying value	Accumulated amortization	Impairment	Net carrying value
Trade names	0.8	(0.1 )	—	0.7
Technology	46.4	(2.6 )	—	43.8
Customer relationships	11.1	(0.7 )	—	10.4
In-process research and development	16.8	—	(1.2 )	15.6
Foreign exchange	0.1	—	—	0.1
Balance, end of period	75.2	(3.4 )	(1.2 )	70.6

Banner's in-process research and development ("IP R&D") is classified as definite-lived or indefinite-lived depending on whether the product has been approved. IP R&D for products that have been approved is classified as a definite-lived intangible asset and is amortized over the life of the product. IPR&D for products that have not been approved is classified as an indefinite-lived intangible asset and either begins to be amortized upon approval or is written-off if the product is not approved. During the three months ended July 31, 2013, the Company curtailed two Banner IP R&D projects which resulted in a \$1.2 million impairment charge.

**Goodwill**

The following table summarizes the changes between October 31, 2012 and July 31, 2013 in the carrying amount of goodwill in total and by reporting segment:

	Commercial	PDS	Corp. & Other	Total
Balance at October 31, 2012	3.5	—	—	3.5
Additions	42.0	—	—	42.0
Impairments	(0.1 )	—	—	(0.1 )
Foreign currency translation adjustments	(0.1 )	—	—	(0.1 )
Balance at July 31, 2013	45.3	—	—	45.3

**5. PREFERRED SHARES AND RESTRICTED VOTING SHARES**

The following table summarizes information regarding the Company's outstanding preferred shares, restricted voting shares and restricted voting share stock options as of July 31, 2013:

	Outstanding	Exercisable
Class I preferred shares series D	150,000	N/A
Restricted voting shares	140,928,525	N/A
Restricted voting share stock options	11,042,625	2,947,975

On December 31, 2012, the Company completed an offering of \$30.0 million offering of transferable subscription rights, with every 13.75 rights entitling each holder of the Company's outstanding restricted voting shares to subscribe for one whole restricted voting share at a price of, at such holder's choice, either US\$3.19 per whole share or CAD\$3.19 per whole share (the "Rights Offering").

Patheon issued 9,403,483 restricted voting shares as a result of the Rights Offering. This issuance represents approximately 7.2% of the Company's restricted voting shares issued and outstanding prior to the Rights Offering. Upon the issuance of these new restricted voting shares, the Company had 139,701,375 restricted voting shares outstanding. The Company used the proceeds from the Rights Offering to partially finance the Banner Acquisition.

An affiliate of JLL Partners Fund V, L.P., a related party of the Company ("JLL Partners Fund V"), exercised its subscription rights in full, including its over-subscription privilege, up to the full amount of the Rights Offering. All excess subscription payments received from over-subscribing rights holders, including JLL Partners Fund V, were returned, without interest or penalty. As a result of the rights offering, JLL Partners Fund V received 5,786,805 restricted voting shares (524,392 of which were received pursuant to the exercise of its over-subscription privilege), and as a result, JLL Partners Fund V's

13

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

ownership of restricted voting shares, together with its affiliates, is approximately 55.7% of the Company's issued and outstanding restricted voting shares.

The Rights Offering contained a subscription price that was less than the fair value of the Company's restricted voting shares on the last day the rights could be exercised, which created a bonus element similar to a stock dividend.

Because of this bonus element, the Company adjusted both the weighted-average basic and diluted shares outstanding immediately prior to the completion of the Rights Offering by multiplying those weighted-average shares by an adjustment factor that represented the fair value per restricted voting share immediately prior to the exercise of the basic and over-subscription privileges under the Rights Offering divided by the theoretical ex-rights fair value per restricted voting share immediately prior to the exercise of the basic and over-subscription privileges under the Rights Offering. Weighted-average basic and diluted shares outstanding and net loss per weighted-average basic and diluted share for the three and nine months ended July 31, 2012 as originally reported and as adjusted for this bonus element were as follows:

	As originally reported	As adjusted	Effect of change
Three months ended July 31, 2012			
Weighted-average basic and diluted shares outstanding	129,168	129,639	471
Net loss per basic and diluted share	0.120	0.119	(0.001 )
	As originally reported	As adjusted	Effect of change
Nine months ended July 31, 2012			
Weighted-average basic and diluted shares outstanding	129,168	129,639	471
Net loss per basic and diluted share	(0.647 )	(0.645 )	0.002

## 6. SEGMENTED INFORMATION

The Company is organized and managed in two business segments: CMO and PDS. These segments are organized around the service activities provided to the Company's customers.

	As of and for the three months ended July 31, 2013			
	Commercial	PDS	Corp. & Other	Total
	\$	\$	\$	\$
Revenues	227.8	37.9	—	265.7
Adjusted EBITDA	39.6	12.0	(10.6 )	41.0
Depreciation	11.3	0.9	0.2	12.4
Impairment charge	1.2	—	—	1.2
Capital expenditures	14.3	1.4	—	15.7
	As of and for the three months ended July 31, 2012			
	Commercial	PDS	Corp. & Other	Total
	\$	\$	\$	\$
Revenues	168.3	35.4	—	203.7
Adjusted EBITDA	36.6	8.6	(8.8 )	36.4
Depreciation	7.9	1.2	0.2	9.3

Capital expenditures	14.7	0.5	0.1	15.3
----------------------	------	-----	-----	------

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	As of and for the nine months ended July 31, 2013			
	Commercial	PDS	Corp. & Other	Total
	\$	\$	\$	\$
Revenues	627.4	105.7	—	733.1
Adjusted EBITDA	99.1	27.6	(31.5)	95.2
Total assets	863.2	70.9	137.0	1,071.1
Depreciation	32.2	2.8	0.6	35.6
Goodwill	45.3	—	—	45.3
Impairment charge	11.3	—	—	11.3
Capital expenditures	30.7	3.4	0.1	34.2

  

	As of and for the nine months ended July 31, 2012			
	Commercial	PDS	Corp. & Other	Total
	\$	\$	\$	\$
Revenues	438.1	101.0	—	539.1
Adjusted EBITDA	56.7	19.1	(24.8)	51.0
Total assets	587.9	68.0	98.9	754.8
Depreciation	26.3	3.8	0.7	30.8
Goodwill	3.4	—	—	3.4
Impairment charge	55.1	2.8	—	57.9
Capital expenditures	29.4	2.5	1.0	32.9

Cash and cash equivalents as well as deferred tax assets are considered to be part of "Corp. & Other" in the breakout of total assets shown above. In the first quarter of fiscal 2013, the Company announced the closure of its Olds, Canada facility and recorded impairment charges of \$10.1 million to its CMO segment. In the third quarter of fiscal 2013, the Company curtailed two Banner IP R&D projects resulting in an impairment charge of \$1.2 million. Additionally, during the second quarter of fiscal 2013 the CMO segment recorded product returns from the packaging site and inventory write-offs of \$6.1 million, related to a manufacturing problem at Banner due to a change in raw materials and operational processes qualified prior to the acquisition that did not perform as expected, which are reflected in gross profit in the consolidated statements of operations.

The Company evaluates the performance of its segments based on segment Adjusted EBITDA. Commencing in fiscal 2013, the Company has revised its calculation of Adjusted EBITDA to exclude stock-based compensation expense, consulting costs related to the Company's operational initiatives, purchase accounting adjustments and acquisition-related litigation expenses (as discussed in Note 10). The Company has determined that excluding these items from Adjusted EBITDA better reflected the underlying performance of the Company's segments. Based on the revisions to the Company's segment performance measure, the Company has recast the presentation of its segment results for the prior periods to be consistent with the current period presentation. Following the change in the segment performance measure, the Company's definition of Adjusted EBITDA is now income (loss) from continuing operations before repositioning expenses, interest expense, foreign exchange losses reclassified from other comprehensive income (loss), refinancing expenses, acquisition and integration costs (including certain product returns and inventory write-offs recorded in gross profit), gains and losses on sale of capital assets, income taxes, asset impairment charges, depreciation and amortization, stock-based compensation expense, consulting costs related to the Company's operational initiatives, purchase accounting adjustments, acquisition-related litigation expenses and other income and expenses. The Company's presentation of Adjusted EBITDA may not be comparable to similarly-titled

measures used by other companies and is not equivalent to "Consolidated EBITDA" as defined in the Credit Agreement (as discussed in Note 12).

Below is a reconciliation of Adjusted EBITDA to its closest U.S. GAAP measure.

15

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
	\$	\$	\$	\$
Total Adjusted EBITDA	41.0	36.4	95.2	51.0
Depreciation and amortization	(12.4	)(9.3	)(35.6	)(30.8
Repositioning expenses	(4.5	)(0.1	)(11.0	)(6.9
Acquisition and integration costs	(1.2	)—	(15.4	)—
Interest expense, net	(12.6	)(6.8	)(35.0	)(19.8
Impairment charge	(1.2	)—	(11.3	)(57.9
Gain on sale of capital assets	—	—	1.6	—
(Provision for) benefit from income taxes	(0.9	)(3.3	) 5.5	(3.6
Refinancing expenses	—	—	(29.2	)—
Operational initiatives related consulting costs	(0.4	)(1.0	)(2.3	)(13.3
Acquisition-related litigation expenses	(4.0	)—	(4.0	)—
Stock-based compensation expense	(0.7	)(0.7	)(2.4	)(2.5
Purchase accounting adjustments	—	—	(5.0	)—
Other	1.2	0.3	2.0	0.5
Income (loss) from continuing operations	4.3	15.5	(46.9	)(83.3

As illustrated in the table below, revenues are attributed to countries based on the location of the customer's billing address, capital assets are attributed to the country in which they are located and goodwill is attributed to the country in which the entity to which the goodwill pertains is located:

	As of and for the three months ended July 31, 2013				
	Canada	US	Europe	Other	Total
	\$	\$	\$	\$	\$
Revenues	3.9	155.5	81.7	24.6	265.7
	As of and for the three months ended July 31, 2012				
	Canada	US*	Europe	Other	Total
	\$	\$	\$	\$	\$
Revenues	4.3	109.4	79.8	10.2	203.7
	As of and for the nine months ended July 31, 2013				
	Canada**	US*	Europe	Other	Total
	\$	\$	\$	\$	\$
Revenues	15.4	429.6	226.3	61.8	733.1
Capital assets	114.4	193.2	183.1	1.5	492.2
Goodwill	3.4	31.5	6.9	3.5	45.3

\* Includes Puerto Rico

\*\*Canada assets reflect the fiscal 2013 impairment of Olds, Canada assets.

	As of and for the nine months ended July 31, 2012				
	Canada	US*	Europe ***	Other	Total
	\$	\$	\$	\$	\$
Revenues	9.1	310.8	191.5	27.7	539.1
Capital assets	112.5	144.5	140.7	1.5	399.2
Goodwill	3.4	—	—	—	3.4

\* Includes Puerto Rico

\*\*\* European assets reflect the fiscal 2012 impairment of Swindon assets.



Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

## 7. STOCK-BASED COMPENSATION

The Company has an incentive stock option plan in which directors, officers and key employees of the Company and its subsidiaries, as well as other persons engaged to provide ongoing management or consulting services to Patheon, are eligible to participate. On March 10, 2011, the Company's shareholders approved an amendment to the stock option plan, which, among other things, provides that the maximum number of shares that may be issued under the plan is 15,500,151, which currently represents 11% of the issued and outstanding restricted voting shares. As of July 31, 2013 and 2012, the total number of restricted voting shares issuable under the plan was 15,500,151 shares, respectively, of which there were stock options outstanding to purchase 11,042,625 shares and 13,028,718 shares, respectively, under the plan. Before the March 2011 amendments, the plan provided that the exercise prices of options were determined at the time of grant and could not be less than the weighted-average market price of the restricted voting shares of Patheon on the Toronto Stock Exchange (the "TSX") during the two trading days immediately preceding the grant date. Following the March 2011 amendments, the exercise prices of the options may not be less than the closing price of the restricted voting shares on the TSX (or on such other stock exchange in Canada or the United States on which restricted voting shares may be then listed and posted) on the date of the grant. Options generally expire in no more than 10 years after the grant date and are subject to early expiry in the event of death, resignation, dismissal or retirement of an optionee. Options generally have vesting periods of either three years or five years, with either one-third or one-fifth vesting on each anniversary of the grant date, respectively.

On June 18, 2012 the Company granted 1,291,750 options to its executive committee members with a vesting based upon the parameters that all granted options will have cliff performance vesting which will vest at the earlier of the achievement of an adjusted EBITDA target or five years after date of grant.

For the purposes of calculating the stock-based compensation expense in connection with the Company's incentive stock option plan, the fair value of stock options is estimated at the date of the grant using the Black-Scholes option pricing model and the cost is amortized over the vesting period.

Stock-based compensation expense recorded in the three and nine months ended July 31, 2013 was \$0.7 million and \$2.4 million. Stock-based compensation expense recorded in the three and nine months ended July 31, 2012 was \$0.7 million and \$2.5 million.

A summary of the plan activity during the nine months ended July 31, 2013 is as follows:

(Dollar amounts in Canadian dollars)	Number of shares	Weighted-average exercise price	Weighted-average contractual term	Aggregate intrinsic value
		\$		\$
Outstanding as of October 31, 2012	12,479,677	2.54		15,634,784
Granted	1,610,000	4.16		—
Exercised	(2,227,150 )	2.66		3,113,942
Forfeited	(810,902 )	2.91		1,749,806
Expired	(9,000 )	13.21		—
Outstanding as of July 31, 2013	11,042,625	2.71	7.78	33,109,017
Exercisable as of July 31, 2013	2,947,975	2.69	6.32	9,000,749

The total fair value of shares that vested during the three months ended July 31, 2013 and 2012 was \$2.3 million and \$2.4 million, respectively. As of July 31, 2013, the total unrecognized compensation cost related to the nonvested stock options was \$5.4 million, which is expected to be recognized through the fiscal year ending October 31, 2018, with a weighted-average remaining vesting period of 2.28 years.

8. PENSION AND POST-RETIREMENT BENEFITS

Employee future benefits

The components of net periodic benefit cost for the defined benefit plans and other benefit plans for the nine months ended July 31, 2013 and 2012 were as follows:

17

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	Nine months ended July 31,		2012	
	2013			
	Defined benefit pension plans	Other benefit plans	Defined benefit pension plans	Other benefit plans
	\$	\$	\$	\$
Service cost	1.7	0.1	1.7	—
Interest cost	4.2	0.3	3.8	0.3
Expected return on plan assets	(4.3	) —	(4.0	) —
Amortization of actuarial loss	0.9	—	0.8	—
Net periodic benefit costs	2.5	0.4	2.3	0.3

Amounts for fiscal 2013 include the defined benefit pension plans for Mexico and The Netherlands under which the Company became obligated in connection with the Banner Acquisition.

Based on current information available from actuarial estimates, the Company anticipates that contributions required under its defined benefit pension plans and other benefit plans for fiscal 2013 will be approximately \$6.6 million compared to contributions of \$5.8 million that were made in fiscal 2012. Required contributions to defined benefit pension plans in future years may vary and will be dependent upon a number of variables, including the long-term rate of return on plan assets.

The defined benefit and other benefit plans estimates above do not include the unfunded termination indemnities related to the employees of the Company's Italian subsidiary. In accordance with Italian severance pay statutes, an employee benefit is accrued for service to date and is payable when the employee's employment with the Company ceases. The termination indemnity liability is calculated in accordance with local civil and labor laws based on each employee's length of service, employment category and remuneration. The termination liability is adjusted annually by a cost-of-living index provided by the Italian government. Although there is no vesting period, the Italian government has established private accounts for these benefits and has required the Company to contribute \$3.8 million and \$3.2 million in fiscal 2013 and 2012, respectively, to these accounts, with additional contributions in the future. The liability recorded in the consolidated balance sheets is the amount to which the employees would be entitled if their employment with the Company ceased. The related expenses for the nine months ended July 31, 2013 and 2012 was \$2.3 million and \$2.3 million, respectively.

The defined benefit and other benefit plans estimates above also do not include the unfunded termination indemnities related to the employees of the Company's Mexican subsidiary, which the Company acquired as part of the Banner Acquisition. According to the Mexican labor law, a termination indemnity is payable when a company terminates an employment relationship without justified cause (as defined in the labor law) and is equal to three months of salary and benefits, plus 20 days of salary and benefits per each credited service year. The termination indemnity liability is unfunded; therefore the liability is recognized through a reserve calculated by the actuaries. The related expected expense for fiscal 2013 is less than \$0.1 million, and the reserve is recorded on the consolidated balance sheet as of July 31, 2013.

The employee future benefit expense in connection with defined benefit pension plans, other post retirement benefit plans and the unfunded termination indemnities for the nine months ended July 31, 2013 and 2012 was \$5.2 million and \$4.9 million, respectively.

## 9. REPOSITIONING EXPENSE

During the three and nine months ended July 31, 2013, the Company incurred \$4.5 million and \$11.0 million, respectively, in repositioning expenses, which related to Banner synergy initiatives; the plan of termination the

Company announced on May 9, 2012 (the "Plan of Termination"), which is discussed below; restructuring initiatives at the Bourgoin, France facility; and the shutdown of the Caguas facility. During the three and nine months ended July 31, 2012, the Company incurred \$0.1 million and \$6.9 million in repositioning expenses, all of which related to the Plan of Termination and the shutdown of the Caguas facility.

On May 9, 2012, the Company announced the Plan of Termination to reduce the Company's workforce by approximately 91 employees across the Company's global PDS and CMO segments. In connection with the Plan of Termination, the Company recorded approximately \$4.4 million of estimated expenses associated with employee termination benefits during fiscal 2012. The Company anticipates that it may further adjust the size of the workforce at the Swindon or other facilities as it continues its transformation process.

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

The following is a summary of these expenses and other charges associated with operational improvements (collectively "repositioning expenses") as of and for the three and nine months ended July 31, 2013 and 2012:

	As of and for the three months ended July 31, 2013			
	Commercial	PDS	Corporate	Total
	\$	\$	\$	\$
Total repositioning liabilities at April 30, 2013				7.7
Employee-related expenses	4.5	(0.3	) 0.2	4.4
Consulting, professional and project management costs	0.1	—	—	0.1
Total expenses	4.6	(0.3	) 0.2	4.5
Repositioning expenses paid, net of reimbursements				(5.4
Total repositioning liabilities at July 31, 2013				6.8

	As of and for the three months ended July 31, 2012			
	Commercial	PDS	Corporate	Total
	\$	\$	\$	\$
Total repositioning liabilities at April 30, 2012				9.2
Employee-related expenses	0.1	—	—	0.1
Total expenses	0.1	—	—	0.1
Repositioning expenses paid				(0.9
Foreign exchange				(0.4
Total repositioning liabilities at July 31, 2012				8.0

	As of and for the nine months ended July 31, 2013			
	Commercial	PDS	Corporate	Total
	\$	\$	\$	\$
Total repositioning liabilities at October 31, 2012				5.5
Employee-related expenses	6.7	0.3	3.7	10.7
Consulting, professional and project management costs	0.3	—	—	0.3
Total expenses	7.0	0.3	3.7	11.0
Repositioning expenses paid, net of reimbursements				(9.7
Total repositioning liabilities at July 31, 2013				6.8

	As of and for the nine months ended July 31, 2012			
	Commercial	PDS	Corporate	Total
	\$	\$	\$	\$
Total repositioning liabilities at October 31, 2011				6.7
Employee-related expenses	4.4	1.3	—	5.7
Consulting, professional and project management costs	1.2	—	—	1.2
Total expenses	5.6	1.3	—	6.9
Repositioning expenses paid				(5.6
Total repositioning liabilities at July 31, 2012				8.0

## 10. OTHER INFORMATION

Foreign exchange



Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

During the three and nine months ended July 31, 2013, the Company recorded foreign exchange losses of nil and \$1.5 million. These losses were primarily from operating exposures, partially offset by hedge gains. During the three and nine months ended July 31, 2012, the Company recorded foreign exchange losses of \$0.4 million and \$0.6 million. These losses were primarily from hedge losses, partially offset by operating gains.

Contingencies

On December 10, 2012, Procaps S.A. ("Procaps") filed a complaint against the Company in the United States District Court for the Southern District of Florida (Case No. 12-cv-24356-DLG). The complaint involves the Company's collaboration agreement with Procaps, pursuant to which both companies agreed to work together with respect to the marketing of a line of certain prescription pharmaceutical soft-gel development and manufacturing services. Procaps alleges that the Company's acquisition of Banner, a business that historically has generated less than 10% of its revenues from softgel services for prescription pharmaceuticals, transformed the collaboration agreement into an anticompetitive restraint of trade and an agreement between direct competitors to set prices, divide markets and/or allocate geographic territories. Procaps seeks (i) a declaratory judgment that the collaboration agreement must cease and/or terminate; (ii) an injunction requiring that the Company divest all of Banner's soft-gel manufacturing capabilities; and (iii) monetary damages under federal and state antitrust and unfair competition laws, including treble damages for violations of the Sherman Act. The Company subsequently answered Procaps' complaint and filed its affirmative defenses to the complaint. On May 15, 2013, Procaps served its supplemental initial disclosures pleading damages. The parties are currently conducting discovery and trial is scheduled to commence in June 2014.

The Company has not included any accrual in the consolidated financial statements as of July 31, 2013 related to the matter as a result of its assessment that the likelihood of a material loss in connection with the matter is not probable. Due to the early stage of the lawsuit, an estimate of the potential damages or range of damages cannot be made at this time. However, an adverse outcome in this matter could have a material adverse effect on the Company's business, results of operations and financial condition.

One putative class action and four individual plaintiff actions are pending in the United States against one of the Company's customers in connection with the recall of certain lots of allegedly defective products manufactured by the Company for the customer. The Company has also been named in the putative class action and in three of the individual plaintiff actions. The customer has given the Company notice of its intent to seek indemnification from the Company for all damages, costs and expenses, pursuant to the manufacturing services agreement between the customer and the Company. As these cases are at an early stage, the Company is unable to estimate the number of potential claimants or the amount of potential damages for which the Company may be directly or indirectly liable in the above actions.

11. FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT

The Company has determined the estimated fair values of its financial instruments based on appropriate valuation methodologies; however, considerable judgment is required to develop these estimates. The fair values of the Company's financial instruments are not materially different from their carrying values.

As of October 31, 2012, the carrying amount of the financial assets that the Company has pledged as collateral for its long-term debt facilities was \$131.2 million. The Company's Credit Agreement (as discussed in Note 12) is not collateralized by accounts receivable and inventory.

Fair value measurements

The fair value is principally applied to financial assets and liabilities such as derivative instruments consisting of foreign exchange forward contracts and collars. The following table provides a summary of the financial assets and liabilities that are measured at fair value as of July 31, 2013 and October 31, 2012:





Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

## Assets measured at fair value

	Fair value measurement at July 31, 2013 using:				Fair value measurement at October 31, 2012 using:			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$	\$	\$	\$	\$
Derivatives designated as hedging instruments:								
Foreign exchange forward contracts	—	—	—	—	—	2.1	—	2.1
Total assets	—	—	—	—	—	2.1	—	2.1
Contingent consideration receivable	—	—	0.3	0.3	—	—	0.3	0.3
Total assets	—	—	0.3	0.3	—	—	0.3	0.3

## Liabilities measured at fair value

	Fair value measurement at July 31, 2013 using:				Fair value measurement at October 31, 2012 using:			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$	\$	\$	\$	\$
Derivatives designated as hedging instruments:								
Foreign exchange forward contracts	—	1.9	—	1.9	—	—	—	—
Foreign exchange collars	—	0.9	—	0.9	—	0.7	—	0.7
Total liabilities	—	2.8	—	2.8	—	0.7	—	0.7

Level 1 - Based on quoted market prices in active markets.

Level 2 - Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly.

Level 3 - Unobservable inputs that are not corroborated by market data.

The following table presents the fair value of the Company's derivative financial instruments and their classifications on the consolidated balance sheets as of July 31, 2013 and October 31, 2012:

## Fair values of derivative instruments

	Asset derivatives as of July 31, 2013		Asset derivatives as of October 31, 2012	
	Balance sheet location	Fair value \$	Balance sheet location	Fair value \$
Derivatives designated as hedging instruments:				
Foreign exchange forward contracts	Prepaid expenses and other	—	Prepaid expenses and other	1.8
Foreign exchange forward contracts	Other long-term assets	—	Other long-term assets	0.3
Total designated derivatives		—		2.1
Contingent consideration receivable	Other long-term assets	0.3	Other long-term assets	0.3
Total non-designated derivatives		0.3		0.3

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	Liability derivatives as of July 31, 2013		Liability derivatives as of October 31, 2012	
	Balance sheet location	Fair value	Balance sheet location	Fair value
		\$		\$
Derivatives designated as hedging instruments:				
Foreign exchange forward contracts	Other long-term liabilities	0.8	Other long-term liabilities	—
Foreign exchange forward contracts	Accounts payable and accrued liabilities	1.1	Accounts payable and accrued liabilities	0.3
Foreign exchange collars	Accounts payable and accrued liabilities	0.9	Other long-term liabilities	0.4
Total designated derivatives		2.8		0.7

On August 31, 2012, the Company completed the sale of its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions. The total consideration for the sale of this business was approximately \$2.7 million, of which \$1.35 million was paid in cash at closing (subject to the retention of certain amounts in escrow) and \$1.35 million will be paid in 24 months from the closing date if certain revenue targets are met by the new owner.

The \$1.35 million that will be paid 24 months following closing is treated as a contingent consideration receivable for accounting purposes. The contingent consideration receivable was valued at \$0.3 million on the closing date at fair value based upon the present value of the agreed-upon revenue targets. The fair value of the contingent consideration receivable will be marked to market on a quarterly basis with an adjustment to the related receivable and the gain/loss on sale of assets.

There was no change in the fair value of the Company's Level 3 financial instrument as of July 31, 2013.

#### Foreign exchange forward contracts and other hedging arrangements

The Company utilizes financial instruments to manage the risk associated with fluctuations in foreign exchange and interest rates. The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking various hedge transactions.

As of July 31, 2013, the Company's Canadian operations had entered into foreign exchange forward contracts to sell an aggregate amount of US\$94.8 million. These contracts hedge the Canadian operations' expected exposure to U.S. dollar denominated receivables and mature at the latest on April 1, 2015, at an average exchange rate of \$1.0129 Canadian. The mark-to-market value of these financial instruments as of July 31, 2013 was an unrealized loss of \$1.9 million, which has been recorded in accumulated other comprehensive income in shareholders' equity, net of associated income tax.

As of July 31, 2013, the Company's Canadian operations had entered into foreign exchange forward contracts to sell an aggregate amount of €2.0 million. These contracts hedge the Canadian operations' expected exposure to Euro denominated receivables and mature at the latest on October 8, 2013, at an average exchange rate of \$1.2811 Canadian. The mark-to-market value of these financial instruments as of July 31, 2013 was an unrealized loss of \$0.1 million, which has been recorded in accumulated other comprehensive income in shareholders' equity, net of associated income tax.

As of July 31, 2013, the Company's Canadian operations had entered into foreign exchange collars to sell an aggregate amount of US\$36.2 million. These contracts hedge the Canadian operations' expected exposure to U.S. dollar denominated receivables and mature at the latest on July 2, 2014, at an average exchange rate of \$0.9950 Canadian. The mark-to-market value of these financial instruments as of July 31, 2013 was an unrealized loss of \$0.8 million, which has been recorded in accumulated other comprehensive income in shareholders' equity, net of associated income tax.

**Risks arising from financial instruments and risk management**

The Company's activities expose it to a variety of financial risks: market risk (including foreign exchange and interest rate), credit risk and liquidity risk. The Company's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company's financial performance. The Company uses derivative financial instruments to hedge certain risk exposures. The Company does not purchase any derivative financial instruments for speculative purposes.

Financial risk management is the responsibility of the Company's corporate finance team. The corporate finance team works with the Company's operational personnel to identify, evaluate and, where appropriate, hedge financial risks. The

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

Company's corporate finance team also monitors material risks and discusses them with the Audit Committee of the Board of Directors.

Foreign exchange risk

As of July 31, 2013, the Company operated in Canada, the United States, Italy, France, the United Kingdom, The Netherlands, Mexico and Japan. Foreign exchange risk arises because the value of the local currency receivable or payable for transactions denominated in foreign currencies may vary due to changes in exchange rates ("transaction exposures") and because the non-U.S. dollar denominated financial statements of the Company may vary on consolidation into the reporting currency of U.S. dollars ("translation exposures").

The Company's most significant transaction exposures arise in its Canadian operations. Approximately 90% of the revenues of the Canadian operations and approximately 10% of its operating expenses are transacted in U.S. dollars. As a result, the Company may experience transaction exposures because of volatility in the exchange rate between the Canadian and U.S. dollar. Based on the Company's current U.S. denominated net inflows, as of July 31, 2013, fluctuations of +/-10% would, everything else being equal, have an annual effect on (loss) income from continuing operations before income taxes of approximately +/- \$4.8 million, prior to hedging activities.

The objective of the Company's foreign exchange risk management activities is to minimize transaction exposures and the resulting volatility of the Company's earnings. The Company manages this risk by entering into foreign exchange contracts. As of July 31, 2013, the Company has entered into foreign exchange contracts to cover approximately 80% of its Canadian-U.S. dollar cash flow exposures for fiscal 2013. The Company does not currently hedge any translation exposures.

Translation gains and losses related to certain foreign currency denominated intercompany loans are included as part of the net investment in certain foreign subsidiaries, and are included in accumulated other comprehensive income (loss) in shareholders' equity.

Credit risk

Credit risk arises from cash and cash equivalents held with banks and financial institutions, derivative financial instruments (foreign exchange contracts with positive fair values), and credit exposure to customers, including outstanding accounts receivable. The maximum exposure to credit risk is equal to the carrying value of the financial assets.

The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company regularly assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors. Management also regularly monitors the utilization of credit limits. In cases where the credit quality of a customer does not meet the Company's requirements, a cash deposit is received before any services are provided. As of July 31, 2013 and October 31, 2012, the Company held deposits of \$17.3 million and \$16.4 million, respectively.

Liquidity risk

Liquidity risk arises when financial obligations exceed financial assets available at a particular point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at all times. The Company mitigates liquidity risk by maintaining cash and cash equivalents on-hand and through the availability of funding from credit facilities. As of July 31, 2013, the Company was holding cash and cash equivalents of \$40.9 million and had undrawn lines of credit available to it of \$63.4 million.

12. LONG-TERM OBLIGATIONS AND OTHER SHORT-TERM BORROWINGS

Long-term debt in the accompanying consolidated balance sheets at July 31, 2013 and October 31, 2012 consists of the following:



Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

	As of July 31, 2013 \$	As of October 31, 2012 \$
Floating LIBOR plus 6.00% with LIBOR floor of 1.25% (currently 7.25%) due December 14, 2018 (the "Secured Term Loan")	570.7	—
Italian subsidized loan with annual interest rate of 0.5%, and maturity date of June 30, 2020	7.0	—
Italian bank loan with Euribor 6-month + 7.1% rate, and maturity date of June 30, 2020	1.0	—
8.625% senior secured notes due April 15, 2017 (the "Notes")	—	280.0
\$85 million secured revolving credit facility maturing December 14, 2017, bearing interest ranging from 5.8% to 7.75% (the "Secured Revolving Facility")	42.3	—
\$75 million senior secured revolving loan facility maturing April 23, 2014, bearing interest ranging from 4.03% to 5.75% based upon floating LIBOR, US, or CAD prime, or federal funds effective rates, plus applicable margins (the "ABL")	—	30.7
Total long-term debt outstanding	621.0	310.7
Less original issue discount, net of accumulated amortization of \$1.5 million	(15.8 )	—
Less current portion	(6.8 )	—
Balance, end of the period	598.4	310.7

On December 14, 2012, the Company completed the refinancing of its existing debt (the "Refinancing"), pursuant to which it entered into a credit agreement (the "Credit Agreement") for a secured term loan in the amount of \$575.0 million (the "Secured Term Loan") and a secured revolving credit facility of up to \$85.0 million (the "Secured Revolving Facility" and, together with the Secured Term Loan, the "Credit Facility"). Up to \$30.0 million of the Secured Revolving Facility is available for letters of credit. The Secured Term Loan matures on December 14, 2018, and the Secured Revolving Facility matures on December 14, 2017. The Secured Term Loan bears interest at a rate per annum equal to, at the option of the Company, LIBOR plus 6.00%, with a LIBOR "floor" of 1.25%, or an alternate base rate plus 5.00%, with an alternate base rate "floor" of 2.25%. Borrowings under the Secured Revolving Facility bear interest for eurodollar loans at Libor plus 5.50% and base rate loans at the base rate plus 4.50%. The Company will also pay a commitment fee of 0.50% per annum on the unused portion of the Secured Revolving Facility with a step down to 0.375% when the First Lien Leverage Ratio (as defined in the Credit Agreement) is less than or equal to 3.00 to 1.00.

First Lien Leverage Ratio is generally defined in the Credit Agreement as the ratio of (i) the sum of the aggregate principal amount of the Company's and its restricted subsidiaries' indebtedness for borrowed money, principal amount of capital lease obligations and debt obligations evidenced by promissory notes or similar instruments plus the unrestricted cash of the Company and its restricted subsidiaries, in each case as set forth in the Credit Agreement, to (ii) Consolidated EBITDA. Consolidated EBITDA is generally defined in the Credit Agreement as income (loss) from continuing operations before repositioning expenses, interest expense, foreign exchange losses reclassified from other comprehensive income (loss), refinancing expenses, acquisition-related costs, gains and losses on sale of capital assets, income taxes, asset impairment charges, depreciation and amortization, stock-based compensation expense, consulting costs related to the Company's operational initiatives, purchase accounting adjustments, other income and expenses, non-cash charges, expenses related to the Banner Acquisition, pro forma cost savings from operational excellence initiatives and plant consolidations, pro forma synergies from the Banner Acquisition, and proceeds from business interruption insurance, among other adjustments. Consolidated EBITDA is not equivalent to Adjusted EBITDA, which, as discussed in Note 6, is the Company's measure of segment performance.

The Company is required to make the following mandatory prepayments in respect of the Secured Term Loan: (i) 50% of Excess Cash Flow (as defined in the Credit Agreement) when the Company maintains a First Lien Leverage Ratio of greater than 3.50 to 1.00, with step downs to (a) 25% when the Company maintains a First Lien Leverage Ratio of less than or equal to 3.50 to 1.00 but greater than 3.00 to 1.00 and (b) 0% when the Company maintains a First Lien Leverage Ratio of less than or equal to 3.00 to 1.00; (ii) 100% of the net cash proceeds of certain asset sales (including insurance and condemnation proceeds), subject to thresholds, reinvestment rights and certain other exceptions; and (iii) 100% of the net cash proceeds of issuances of debt obligations, subject to certain exceptions and thresholds. Excess Cash Flow is generally defined in the Credit Agreement as Consolidated EBITDA (as defined in the Credit Agreement) plus, without duplication, (i) decreases in working capital, (ii) extraordinary or nonrecurring income or gains and (iii) certain other adjustments, minus, without duplication, (a) interest, (b) taxes, (c) increases in working capital, (d) capital expenditures paid in cash and (e) certain other adjustments, in each case as set forth in the Credit Agreement. In the event the Secured Term Loan is prepaid, refinanced, substituted or replaced (including by way of amendment) in whole or in part prior to December 14, 2013 concurrently with the incurrence of indebtedness similar to

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

the Secured Term Loan with a lower all-in yield than that of the Secured Term Loan, any amounts so prepaid, refinanced, substituted or replaced will be subject to a prepayment fee of 1.00%.

Under the Credit Agreement, the Company is required to maintain a First Lien Leverage Ratio below a certain amount for each of the Testing Periods as set forth in the Credit Agreement. For purposes of the Credit Agreement, a Testing Period means a single period consisting of the most recent four consecutive fiscal quarters ending on the covenant determination date. The following table discloses the maximum permitted First Lien Leverage Ratios permitted under the Credit Agreement:

Testing Period Ending	Maximum Ratio
April 30, 2013 through July 31, 2014	5.50 to 1.00
October 31, 2014 through July 31, 2015	5.00 to 1.00
October 31, 2015 through April 30, 2016	4.75 to 1.00
July 31, 2016 through October 31, 2016	4.50 to 1.00
January 31, 2017 and thereafter	4.25 to 1.00

The Credit Agreement also provides for (i) certain representations, warranties and affirmative covenants, (ii) certain negative covenants in addition to the requirement to maintain the First Lien Leverage Ratio levels described above, including limitations on incurring indebtedness, liens, fundamental changes, asset sales, investments, dividends and repayment of certain indebtedness, and transactions with affiliates, in each case with baskets, thresholds and exceptions, and (iii) certain events of default, including for non-payment of principal and interest, breach of affirmative or negative covenants, certain cross defaults, change in control, bankruptcy events, certain ERISA events, certain unsatisfied judgments and actual or asserted invalidity of guarantees or security documents.

The Company's failure to maintain the required First Lien Leverage Ratio or its breach of the other covenants and requirements contained in the Credit Agreement could result in an event of default, which may allow the Company's lenders to accelerate the Company's debt and may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. As of July 31, 2013, the Company was in compliance with the covenants and other requirements in the Credit Agreement.

Provided that the Company is in compliance with the First Lien Leverage Ratio test and no default under the Credit Agreement is continuing or would result therefrom, the covenant in the Credit Agreement that limits the Company's ability to pay dividends or make other distributions to its shareholders generally permits (with certain exceptions and qualifications) the Company to pay dividends or make such distributions in an aggregate amount, when taken together with the aggregate amount of any prepayment, repurchase, redemption or defeasance of subordinated indebtedness, not to exceed (i) \$15.0 million plus (ii) (a) \$7.5 million plus (b) the aggregate amount of Excess Cash Flows for all fiscal years beginning with fiscal 2013 (net of required prepayments) and proceeds from equity issuances. The Company historically has not paid dividends on its restricted voting shares.

The Credit Facility is guaranteed by certain wholly owned subsidiaries of the Company and secured by a first priority pledge on substantially all of the assets of the Company and the subsidiary guarantors, in each case subject to certain exceptions.

As part of the Refinancing, effective December 14, 2012, the Company terminated all commitments and repaid all amounts owed under its \$75.0 million asset-based revolving credit facility (the "ABL"). In addition, on November 26, 2012, the Company commenced a cash tender offer for its \$280 million of 8.625% senior secured notes (the "Notes"). As of 12:00 midnight, New York City time, on December 13, 2012, \$279.4 million principal amount of the Notes had been tendered and not validly withdrawn, representing approximately 99.80% of the aggregate outstanding principal amount of the Notes. On December 14, 2012, the Company paid an aggregate of approximately \$307.2 million in order to purchase the Notes tendered prior to December 14, 2012. In addition, the Company deposited with the trustee in respect of the Notes sufficient funds to redeem the remaining outstanding Notes on January 23, 2013 and pay accrued and unpaid interest thereon. As a result, the Company was released from its obligations under the Notes and



the indenture governing the Notes pursuant to the satisfaction and discharge provisions of such indenture.

During the nine months ended July 31, 2013, the Company incurred \$29.2 million of refinancing expense comprised of a \$23.8 million early redemption penalty related to the repayment of the Notes, and \$5.3 million related to the write-off of deferred financing costs on the Notes and the ABL and other related charges. In addition, new creditor and third party fees of

25

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

\$22.7 million were capitalized in long term assets and an original issue discount of \$17.3 million was capitalized and netted against the carrying value of the related debt. Both the new fees and the original issue discount will be amortized to interest expense over the term of the Credit Agreement.

During the three months ended July 31, 2013, the Company received assistance from the Italian government in the form of two loans. One loan is a subsidized loan for approximately €6.0 million, of which the Company received €5.4 million during the three months ended July 31, 2013 with the remaining €0.6 million to be received in the fiscal year ending October 31, 2014 ("fiscal 2014"). The subsidized loan has an annual interest rate of 0.5%, a maturity date of June 30, 2020 with fixed semi-annual payments. The other loan is a bank loan for approximately €0.7 million, of which the Company received €0.6 million during the three months ended July 31, 2013 with the remaining €0.1 million to be received in fiscal 2014. The bank loan has a Euribor 6-month + 7.1% annual interest rate, a maturity date of June 30, 2020 and six variable semi-annual payments beginning December 2017.

In addition to the two loans above, the Company was also approved to receive a grant for approximately €0.7 million to reimburse the Company for research and development costs incurred and was booked against the cost of goods sold in the three months ended July 31, 2013.

### 13. RELATED PARTY TRANSACTIONS

Revenues for contract manufacturing from a company controlled by Joaquin B. Viso (the "Viso Affiliate"), a director and significant shareholder of the Company, were nil for the three and nine months ended July 31, 2013, and \$0.2 million and \$0.3 million for the three and nine months ended July 31, 2012. These transactions were conducted in the normal course of business and are recorded at the exchanged amounts. Accounts receivable at July 31, 2013 and October 31, 2012 were nil, respectively, resulting from these transactions. In addition, Patheon manufactures a product for a third party for which the product's intellectual property is owned by the Viso Affiliate. The manufacturing agreement was originally contracted between the third party and the Viso Affiliate, but has been administered directly between Patheon and the third party on normal commercial terms since 2003.

As of July 31, 2013 and October 31, 2012, the Company had an investment of \$6.0 million and \$4.0 million, respectively, representing an 18% interest in two Italian companies (collectively referred to as "BSP Pharmaceuticals") whose largest investor was previously an officer of the Company until December 31, 2009. These companies specialize in the manufacture of cytotoxic pharmaceutical products. As a result of the shareholders' agreement with the other investors in BSP Pharmaceuticals that provides the Company with significant influence over BSP Pharmaceuticals' operations, the Company accounts for its investment in BSP Pharmaceuticals using the equity method. Accordingly, for the nine months ended July 31, 2013 and 2012, the Company recorded investment income of approximately \$1.8 million and \$0.4 million, respectively.

In connection with its investment in BSP Pharmaceuticals, the Company has a management services agreement with BSP Pharmaceuticals that provides on-going sales and marketing services, and provided engineering and operational services during the construction of the BSP facility which was completed in 2008. There were no management fees recorded under this agreement for the three months ended July 31, 2013 and 2012, respectively. There was no accounts receivable balance at July 31, 2013 and October 31, 2012 in connection with the management services agreement, respectively. These services were conducted in the normal course of business and are recorded at the exchanged amounts.

In connection with certain of BSP Pharmaceuticals' bank financing, the Company had made commitments that it would not dispose of its interest in BSP Pharmaceuticals prior to January 1, 2011, and if needed, on an ongoing basis irrevocably inject equity (pro-rata) in order to ensure BSP complies with certain specific bank covenants. The Company has not made any injections since fiscal 2010.

#### 14. INCOME TAXES

The Company accounts for income taxes under FASB ASC 740, Income Taxes ("ASC 740"). The Company calculates its quarterly tax provision consistent with the guidance provided by ASC 740-270, whereby the Company forecasts its estimated annual effective tax rate then applies that rate to its year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. The Company has recorded valuation allowances against certain Canadian and foreign jurisdictions due to insufficient evidence supporting the Company's ability to use these assets in the future.

26

---

Table Of Contents

Notes to Unaudited Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2013  
(Dollar information in tabular form is expressed in millions of U.S. dollars, except per share information)

During the three months ended January 31, 2013, the Company released \$0.5 million of the valuation allowance against the U.S. deferred tax assets and recognize a tax benefit, due to the creation of deferred tax liabilities from the Banner Acquisition. During the three months ended April 30, 2013, the Company recorded a \$3.0 million discrete tax benefit as a result of changes in tax laws and rates taking effect in 2013. In addition, during the three months ended July 31, 2013, the Company recorded a \$0.4 million discrete tax benefit as a result of changes in tax laws and rate taking effect in 2013.

For the nine months ended July 31, 2013, the Company increased uncertain tax benefits by \$2.7 million related to the Banner Acquisition, of which \$2.1 million was recorded as an adjustment to goodwill. The Company does not reasonably expect material changes to the amount of uncertain tax positions within the next 12 months.

#### 15. BASIC AND DILUTED INCOME (LOSS) PER SHARE

Shares used in basic earnings per share are computed using the weighted-average number of common shares outstanding during each period. Shares used in diluted earnings per share include the dilutive effect of unvested restricted voting share stock options under the incentive stock option plan using the treasury stock method. For the three months ended July 31, 2013 and 2012, 5,054,113 and 52,827 weighted-average restricted voting shares options had a grant price that was less than the average market price. The computation of net income per share did not include 5,988,512 and 12,975,891 outstanding options in the three months ended July 31, 2013 and 2012 because such options were anti-dilutive in nature. The computation of net income per share did not include 11,042,625 and 13,028,718 outstanding options in the nine months ended July 31, 2013 and 2012, respectively, because such options were anti-dilutive in nature.

The components of basic and diluted earnings per share for the three and nine months ended July 31, 2013 and 2012 are as follows:

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
Numerator:				
(Loss) income from continuing operations	\$4.3	\$15.5	\$(46.9 )	\$(83.3 )
(Loss) income from discontinued operations	—	—	—	(0.2 )
Net (loss) income	\$4.3	\$15.5	\$(46.9 )	\$(83.5 )
Denominator: (in thousands of shares)				
Weighted-average number of shares outstanding	140,640	129,639	139,232	129,639
- Basic				
Dilutive effect of restricted voting shares options	5,054	53	—	—
Weighted-average number of shares outstanding	145,694	129,692	139,232	129,639
- Diluted				

The weighted-average number of shares outstanding has been adjusted to reflect the impact of the Rights Offering (as described in Note 5).

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion is designed to provide a better understanding of our consolidated financial statements, including a brief discussion of our business, key factors that impact our performance and a summary of our operating results. You should read the following discussion and analysis of financial condition and results of operations together with our unaudited consolidated financial statements and the related notes beginning on page 1 of this quarterly report on Form 10-Q and our audited financial statements and related notes beginning on page F-1 of our annual report on Form 10-K filed December 18, 2012 (our "2012 Form 10-K"), which have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors including, but not limited to, those set forth under "Item 1A. Risk Factors" of our 2012 Form 10-K. See "Forward Looking Statements."

### Executive Overview

#### Our Company

We are a leading provider of contract manufacturing and development services to the global pharmaceutical industry, offering a wide range of services from developing drug candidates at the pre-formulation stage through the launch, commercialization and production of approved drugs. We have established our position as a market leader by leveraging our scale, global reach, specialized capabilities, broad service offerings, scientific expertise and track record of product quality and regulatory compliance to provide cost-effective solutions to our customers.

We have two reportable segments, CMO and PDS. Our CMO business manufactures prescription products in sterile dosage forms as well as solid and liquid conventional dosage forms, and we differentiate ourselves by offering specialized manufacturing capabilities relating to high potency, controlled substance, sustained release products and softgel formulations. Our PDS business provides a broad range of development services, including a wide variety of solid and sterile dosage forms. Additionally, our PDS business serves as a pipeline for future commercial manufacturing opportunities.

With the acquisition of Sobel USA Inc. and Banner Pharmacaps Europe B.V. (collectively, "Banner") on December 14, 2012 (the "Banner Acquisition"), we have now expanded our service offering to include the development, licensing and commercialization of proprietary prescription, over the counter and nutritional products while leveraging the combined expertise and capabilities of Banner and Patheon. Banner was a leading provider of softgel formulations with research labs and manufacturing facilities in the US, Canada, Netherlands, and Mexico.

#### Selected Financial Results

The following is a summary of certain key financial results for the three months ended July 31, 2013 (a more detailed discussion is contained in "Results of Operations" below):

• Revenues for the three months ended July 31, 2013 increased \$62.0 million, or 30.4%, to \$265.7 million, from \$203.7 million for the three months ended July 31, 2012.

• Gross profit for the three months ended July 31, 2013 increased \$15.6 million, or 28.1%, to \$71.1 million from \$55.5 million for the three months ended July 31, 2012.

• Income from continuing operations for the three months ended July 31, 2013 was \$4.3 million, compared to \$15.5 million for the three months ended July 31, 2012.

• Adjusted EBITDA for the three months ended July 31, 2013 increased \$4.6 million to \$41.0 million, from \$36.4 million for the three months ended July 31, 2012.

#### Strategic Initiatives

During the fiscal year ending October 31, 2013 ("fiscal 2013"), we have continued to advance our strategic transformation plan. The following are certain key activities related to the plan that we have undertaken in fiscal 2013.



On March 7, 2013, we informed affected employees of the planned shutdown of the Olds, Canada facility by October 31, 2013. We expect to incur approximately \$3.7 million in severance and retention expenses along with \$1.0 million in closing costs. These costs are in addition to the non-cash impairment charge relating to the Olds, Canada facility of \$10.1 million booked in the first quarter of fiscal 2013, which resulted from a review of all facilities that formed part of the Banner Acquisition. We expect this closure will save approximately \$10.0 million in cash expenses on an annual basis.

On February 28, 2013, we entered into a sale-leaseback agreement for the Caguas facility for \$7.0 million. The lease is a month-to-month tenancy with a target, non-binding, termination date of December 31, 2013.

On December 31, 2012, we completed our subscription rights offering (the "Rights Offering"). The Rights Offering was fully subscribed for with gross proceeds totaling approximately \$30.0 million.

On December 14, 2012, we completed the Banner Acquisition. We acquired Banner for a net aggregate purchase price of approximately \$269.0 million. Banner is the world's second largest pharmaceutical business focused on delivering proprietary softgel formulations, with four manufacturing facilities, significant proprietary technologies and products, and leading positions in some of the industry's fastest-growing product categories. Banner currently has research labs and manufacturing facilities in the United States, The Netherlands, Canada and Mexico.

On December 14, 2012, in connection with the closing of the Banner Acquisition, we entered into a new credit facility (the "Credit Facility"), which is comprised of (i) a \$575.0 million secured term loan due December 14, 2018 (the "Secured Term Loan") and (ii) a \$85 million secured revolving credit facility maturing December 14, 2017 (the "Secured Revolving Facility") (collectively, the "Refinancing"). Up to \$30.0 million of the Secured Revolving Facility is available for letters of credit. We used the Credit Facility to finance the Banner Acquisition, repurchase our \$280.0 million of 8.625% senior secured notes (the "Notes"), repay all borrowings outstanding under our then-existing \$75.0 million asset-based revolving credit facility (the "ABL") and pay fees and expenses associated with the transactions. Going forward, the Secured Revolving Facility will be available for general corporate purposes.

#### Changes in Our Management and Board

The following is a summary of certain key changes in our management since the beginning of fiscal 2013:

Effective July 10, 2013, Antonella Mancuso, President, Global Commercial Operations and Chief Manufacturing Officer, resigned from her positions with our company.

On January 9, 2013, Aqeel Fatmi, Ph.D., was appointed as Executive Vice President, Global Research & Development over our Banner subsidiaries and Chief Scientific Officer for our company.

On December 17, 2012, in connection with the completion of the Banner Acquisition, Geoffrey Glass was appointed President of Product and Technology Commercialization.

On November 1, 2012, Michael Lehmann joined our company as President of Global PDS.

#### Opportunities and Trends

Our target markets include the highly fragmented global market for the manufacture of finished pharmaceutical dosage forms and for pharmaceutical development services. According to PharmSource, a provider of pharmaceutical outsourcing business information, the CMO market totaled \$13.7 billion in 2011, and may experience marginal growth of 5% to 7% annually through 2016. PharmSource also estimates that the outsourced PDS market (which tends to be more volatile) totaled approximately \$1.4 billion in 2011, with growth projections approaching 8 to 10% annually through 2016.

In addition, the Banner Acquisition provides us with access to new markets, including the nutritional supplement and over-the-counter pharmaceutical markets. The nutritional supplement market totaled approximately \$90 billion worldwide in 2011 according to the Nutrition Business Journal. The over-the-counter pharmaceutical market generated over \$100 billion in 2011 according to Nicholas Hall. The Banner Acquisition also provides us with a portfolio of proprietary prescription compounds. According to IMS Health, the prescription pharmaceuticals market generated \$956 billion globally in 2011.

#### Plant Consolidations

Subsequent to the closing of the Banner Acquisition, we performed a review of Banner's facilities and decided to close our Olds, Canada facility by October 31, 2013. In connection with this decision, we recorded total impairment charges of

29

---



\$10.1 million, of which \$10.0 million related to the long-term assets at the facility and \$0.1 million related to the goodwill allocated to the Olds, Canada reporting unit. The impairment charges reduce assets in the CMO segment by \$10.1 million. The facility assets will remain as held and used until a plan of sale has been initiated and the site is in a condition for immediate sale.

We closed our Carolina facility in Puerto Rico effective January 31, 2009. We completed the sale of this property on February 17, 2012 for a nominal amount. The results of the Carolina operations have been reported in discontinued operations for the nine months ended July 31, 2012.

We previously announced our plan to consolidate our Puerto Rico operations into our manufacturing site located in Manati and sell our plant in Caguas and that additional time was required to transition manufacturing operations from Caguas to Manati due to longer than expected customer regulatory time lines and increased product demand. We now estimate the total project repositioning expenses to be \$13.7 million, of which \$12.9 million has been incurred as of July 31, 2013. Because our business in the Caguas facility is being transferred within the existing site network, its results of operations are included in continuing operations in the consolidated financial statements.

As previously announced, on February 28, 2013, we entered into a sale-leaseback agreement for the Caguas facility for \$7.0 million. The lease agreement is a month to month tenancy with a target, non-binding, termination date of December 31, 2013. We have the option to holdover the lease in the event further time is necessary to complete the transfer out of Caguas to Manati. In the event of a holdover, the term may be extended on a month to month basis. As a result of the sale-leaseback, we recorded a prepaid rent asset for \$1.5 million during the quarter, which we began amortizing immediately. We recognized a gain of \$1.1 million upon the sale.

## Results of Operations

Edgar Filing: PATHEON INC - Form 10-Q

Three Months Ended July 31, 2013 Compared to Three Months Ended July 31, 2012.

(in millions of U.S. dollars, except per share information)	Three months ended July 31,			
	2013	2012	\$ Change	% Change
Revenues	265.7	203.7	62.0	30.4
Cost of goods sold	194.6	148.2	46.4	31.3
Gross profit	71.1	55.5	15.6	28.1
Selling, general and administrative expenses	44.8	29.9	14.9	49.8
Research and development	2.8	—	2.8	—
Repositioning expenses	4.5	0.1	4.4	—
Acquisition and integration costs	1.2	—	1.2	—
Impairment charge	1.2	—	1.2	—
Operating income	16.6	25.5	(8.9)	(34.9)
Interest expense, net	12.6	6.8	5.8	85.3
Foreign exchange loss, net	—	0.4	(0.4)	100.0
Other income, net	(1.2)	(0.5)	0.7	140.0
Income from continuing operations before income taxes	5.2	18.8	(13.6)	(72.3)
Provision for income taxes	0.9	3.3	(2.4)	(72.7)
Income from continuing operations	4.3	15.5	(11.2)	(72.3)
Net income attributable to restricted voting shareholders	4.3	15.5	(11.2)	(72.3)
Basic income per share				
From continuing operations	\$0.031	\$0.120		
From discontinued operations	—	—		
	\$0.031	\$0.120		
Diluted income per share				
From continuing operations	\$0.030	\$0.120		
From discontinued operations	—	—		
	\$0.030	\$0.120		
Weighted-average number of shares outstanding during period—basic (in thousands)	140,640	129,639		
Weighted-average number of shares outstanding during period—diluted (in thousands)	145,694	129,692		

Operating Income (Loss) Summary

Revenues for the three months ended July 31, 2013 increased \$62.0 million, or 30.4%, to \$265.7 million, from \$203.7 million for the three months ended July 31, 2012. Excluding currency fluctuations, revenues for the three months ended July 31, 2013 would have been approximately \$59.1 million higher than the three months ended July 31, 2012. CMO revenues for the three months ended July 31, 2013 increased \$59.5 million, or 35.4%, to \$227.8 million, from \$168.3 million for the three months ended July 31, 2012. An increase of \$66.4 million from the Banner Acquisition was partially offset by a decline at our Puerto Rican operation. PDS revenues for the three months ended July 31, 2013 increased \$2.5 million, or 7.1%, to \$37.9 million, from \$35.4 million for the three months ended July 31, 2012. Excluding the impact of our clinical packaging business that was sold during the fiscal year ended October 31, 2012 ("fiscal 2012"), PDS revenues grew 10.6%.

Gross profit for the three months ended July 31, 2013 increased \$15.6 million, or 28.1%, to \$71.1 million, from \$55.5 million for the three months ended July 31, 2012. The increase in gross profit was primarily due to higher volume from the Banner Acquisition which contributed \$15.3 million at a 23.1% margin. Patheon standalone margin of 28.0% was 0.8 points better than the margin for the three month period ended July 31, 2012. This increase in gross profit margin was driven primarily by the impact of favorable foreign exchange rates.

Selling, general and administrative expenses for the three months ended July 31, 2013 increased \$14.9 million, or 49.8%, to \$44.8 million, from \$29.9 million for the three months ended July 31, 2012. Selling, general and

administrative expenses were higher as a result of the inclusion of Banner's selling, general and administrative costs of \$12.8 million, higher consulting fees of \$0.7 million and higher travel and entertainment and marketing costs. Foreign exchange rates had an unfavorable

impact of \$0.1 million on selling, general and administrative expenses in the three months ended July 31, 2013 versus the same period in the prior year.

Research and development expenses for the three months ended July 31, 2013 were \$2.8 million as a result of the Banner Acquisition. These expenses related to proprietary research and development efforts and consist of salaries and benefits, supplies and other costs.

Repositioning expenses for the three months ended July 31, 2013 increased \$4.4 million, to \$4.5 million, from \$0.1 million for the same period of the prior year primarily due to changes to the organizational alignment within our business as a result of the Banner Acquisition, Caguas closure and consolidation, and realignment of operations at our Bourgoin, France facility, as compared to the expenses related to the plan of termination we announced on May 9, 2012 (the "Plan of Termination") and Caguas closure and consolidation for the three months ended July 31, 2012. Acquisition and integration costs for the three months ended July 31, 2013 were \$1.2 million. These expenses are associated with the Banner Acquisition and related integration activities. In connection with closing the acquisition on December 14, 2012, we incurred, and expect to incur, additional acquisition and integration costs consisting of consultants, system and customer conversions, and other integration-related costs. These costs will be recognized as operating expenses as incurred.

We incurred an impairment charge of \$1.2 million for the three months ended July 31, 2013 related to the impairment of two in-process research and development ("IPR&D") projects that were curtailed at our Banner, High Point facility. Operating income for the three months ended July 31, 2013 decreased \$8.9 million to \$16.6 million (6.2% of revenues), from \$25.5 million (12.5% of revenues) for the three months ended July 31, 2012 as a result of the factors discussed above.

#### Income from Continuing Operations Before Income Taxes

We reported income from continuing operations before income taxes of \$5.2 million for the three months ended July 31, 2013, compared to \$18.8 million for the three months ended July 31, 2012. The operating items discussed above in addition to interest expense were the primary drivers of the year over year variance.

#### Income Taxes

Income taxes were an expense of \$0.9 million for the three months ended July 31, 2013, compared to \$3.3 million for the three months ended July 31, 2012. The decrease in tax expense was primarily driven by a mix of income and losses from operating units and pre-tax losses in some entities for which no tax benefits were recognized in 2013.

#### Income from Continuing Operations and Income Per Share from Continuing Operations

We recorded income from continuing operations for the three months ended July 31, 2013 of \$4.3 million, compared to \$15.5 million for the three months ended July 31, 2012. The basic income per share from continuing operations for the three months ended July 31, 2013 was 3.1¢ compared to income of 12.0¢ for the three months ended July 31, 2012. The diluted income per share from continuing operations for the three months ended July 31, 2013 was 3.0¢ compared to income of 12.0¢ for the three months ended July 31, 2012.

#### Net Income Attributable to Restricted Voting Shareholders and Income Per Share

Net income attributable to restricted voting shares for the three months ended July 31, 2013 was \$4.3 million, or 3.1¢ and 3.0¢ per share for basic and diluted, compared to \$15.5 million, or 12.0¢ per share for both basic and diluted, for the three months ended July 31, 2012.

For the three months ended July 31, 2013 and 2012, 5,054,113 and 52,827 weighted-average restricted voting shares options had a grant price that was less than the average market price. The computation of net loss per share did not include 5,988,512 and 12,975,891 outstanding options in the three months ended July 31, 2013 and 2012 because such options were anti-dilutive in nature.

#### Revenues and Adjusted EBITDA by Business Segment

We evaluate the performance of our segments based on segment Adjusted EBITDA. Commencing in fiscal 2013, we have revised our calculation of Adjusted EBITDA to exclude stock-based compensation expense, consulting costs related to our operational inactivities, purchase accounting adjustments and acquisition-related litigation expenses. We have determined that excluding these items from Adjusted EBITDA better reflected our segments' underlying performance. Based on the revisions



to the definition of Adjusted EBITDA, we recasted the presentation of Adjusted EBITDA for the three and nine months ended July 31, 2012 to be consistent with the current period presentation. Our Adjusted EBITDA (as revised) is now income (loss) from continuing operations before repositioning expenses, interest expense, foreign exchange losses reclassified from other comprehensive income (loss), refinancing expenses, acquisition and integration costs (including certain product returns and inventory write-offs recorded in gross profit), gains and losses on sale of capital assets, income taxes, asset impairment charges, depreciation and amortization, stock-based compensation expense, consulting costs related to our operational initiatives, purchase accounting adjustments, acquisition-related litigation expenses and other income and expenses. "Adjusted EBITDA margin" is Adjusted EBITDA as a percentage of revenues.

Since Adjusted EBITDA is a non-GAAP measure that does not have a standardized meaning, it may not be comparable to similar measures presented by other issuers. In addition, Adjusted EBITDA is not equivalent to "Consolidated EBITDA" as defined in the Credit Agreement (as discussed in "-Liquidity and Capital Resources"). Readers are cautioned that Adjusted EBITDA should not be construed as an alternative to net income (loss) determined in accordance with U.S. GAAP as an indicator of performance. Adjusted EBITDA is used by management as an internal measure of profitability. We have included Adjusted EBITDA because we believe that this measure is used by certain investors to assess our financial performance before non-cash charges and certain costs that we do not believe are reflective of our underlying business.

A reconciliation of Adjusted EBITDA to loss from continuing operations is set forth below:

	Three months ended July 31,		Nine months ended July 31,	
	2013	2012	2013	2012
(in millions of U.S. dollars)	\$	\$	\$	\$
Adjusted EBITDA	41.0	36.4	95.2	51.0
Depreciation and amortization	(12.4	) (9.3	) (35.6	) (30.8
Repositioning expenses	(4.5	) (0.1	) (11.0	) (6.9
Acquisition and integration costs	(1.2	) —	(15.4	) —
Interest expense, net	(12.6	) (6.8	) (35.0	) (19.8
Impairment charge	(1.2	) —	(11.3	) (57.9
Gain on sale of capital assets	—	—	1.6	—
(Provision for) benefit from income taxes	(0.9	) (3.3	) 5.5	(3.6
Refinancing expenses	—	—	(29.2	) —
Operational initiatives related consulting costs	(0.4	) (1.0	) (2.3	) (13.3
Acquisition-related litigation expenses	(4.0	) —	(4.0	) —
Stock-based compensation expense	(0.7	) (0.7	) (2.4	) (2.5
Purchase accounting adjustments	—	—	(5.0	) —
Other	1.2	0.3	2.0	0.5
Income (loss) from continuing operations	4.3	15.5	(46.9	) (83.3

The following provides certain information regarding our business segments for the three months ended July 31, 2013 and 2012:

(in millions of U.S. dollars)	Three months ended July 31,		\$	%
	2013	2012		
	\$	\$	Change	Change
Revenues				
Commercial Manufacturing				
North America	147.9	94.4	53.5	56.7
Europe	79.9	73.9	6.0	8.1
Total Commercial Manufacturing	227.8	168.3	59.5	35.4
Pharmaceutical Development Services	37.9	35.4	2.5	7.1
Total Revenues	265.7	203.7	62.0	30.4
Adjusted EBITDA				
Commercial Manufacturing				
North America	24.9	19.4	5.5	28.4
Europe	14.7	17.2	(2.5)	(14.5)
Total Commercial Manufacturing	39.6	36.6	3.0	8.2
Pharmaceutical Development Services	12.0	8.6	3.4	39.5
Corporate EBITDA	(10.6)	(8.8)	1.8	20.5
Total Adjusted EBITDA	41.0	36.4	4.6	12.6

#### Commercial Manufacturing

Total CMO revenues for the three months ended July 31, 2013 increased \$59.5 million, or 35.4%, to \$227.8 million, from \$168.3 million for the three months ended July 31, 2012. Had local currency exchange rates remained constant to the rates of the three months ended July 31, 2012, CMO revenues for the Patheon legacy entities for the three months ended July 31, 2013 would have been approximately 33.8% higher than the same period of the prior year. Approximately \$66.4 million of the year over year CMO growth resulted from the Banner Acquisition.

North American CMO revenues for the three months ended July 31, 2013 increased \$53.5 million, or 56.7%, to \$147.9 million, from \$94.4 million for the three months ended July 31, 2012. Banner contributed \$66.4 million of the increase, along with strengths in Whitby and Cincinnati, offset by weakness in Puerto Rico.

European CMO revenues for the three months ended July 31, 2013 increased \$6.0 million, or 8.1%, to \$79.9 million, from \$73.9 million for the three months ended July 31, 2012. Had European currency exchange rates remained constant to the rates of the three months ended July 31, 2012, European CMO revenues for the Patheon legacy entities for the three months ended July 31, 2013 would have been approximately 4.4% higher than the same period of the prior year. The increase was primarily due to \$10.1 million from the Banner Acquisition and increases in our Ferentino operations, partially offset by weakness in Monza, Bourgoin and Swindon.

Total CMO Adjusted EBITDA for the three months ended July 31, 2013 increased \$3.0 million to \$39.6 million, from \$36.6 million for the three months ended July 31, 2012. This represents an Adjusted EBITDA margin of 17.4% for the three months ended July 31, 2013 compared to 21.7% for the three months ended July 31, 2012. Had local currency exchange rates and foreign exchange gains and losses remained constant to those of the three months ended July 31, 2012, CMO Adjusted EBITDA for the three months ended July 31, 2013 would have been approximately \$1.9 million lower. The reduction in Adjusted EBITDA margin was driven by higher labor costs and the impact of lower Banner margins, which more than offset the favorable mix and improved margins driven by our operational excellence initiatives at legacy Patheon sites. Repositioning costs of \$4.6 million and an impairment charge of \$1.2 million in the three months ended July 31, 2013 were not included in Adjusted EBITDA.

North American Adjusted EBITDA for the three months ended July 31, 2013 increased \$5.5 million, to \$24.9 million, from \$19.4 million for the three months ended July 31, 2012. Banner contributed \$5.5 million of the increase. Lower volumes in the Patheon legacy North American business was offset by savings from our operational excellence initiatives and lower inventory write-offs.

European Adjusted EBITDA for the three months ended July 31, 2013 decreased \$2.5 million, to \$14.7 million, from \$17.2 million for the three months ended July 31, 2012. Had European currency exchange rates remained constant to

those of the three months ended July 31, 2012, European CMO Adjusted EBITDA for the three months ended July 31, 2013 would have

34

---



been approximately \$0.9 million higher. The decrease was primarily driven by mix and higher labor costs, partially offset by margins from higher volumes, results from our operational excellence initiatives, and \$1.2 million in Adjusted EBITDA from the Banner Acquisition.

#### Pharmaceutical Development Services

Total PDS revenues for the three months ended July 31, 2013 increased by \$2.5 million, or 7.1%, to \$37.9 million, from \$35.4 million for the three months ended July 31, 2012. Excluding the impact of the Clinical Packaging business that was sold in fiscal 2012, PDS revenues grew by 10.6% over the prior period. This growth was primarily due to higher development activities from new contracts across all sites with the exception of Swindon. Had the local currency exchange rates remained constant to the three months ended July 31, 2012, PDS revenues for the three months ended July 31, 2013 would have been approximately \$0.2 million lower.

Total PDS Adjusted EBITDA for the three months ended July 31, 2013 increased \$3.4 million, or 39.5%, to \$12.0 million, from \$8.6 million for the three months ended July 31, 2012. Had local currency exchange rates remained constant to those of the three months ended July 31, 2012, PDS Adjusted EBITDA for the three months ended July 31, 2013 would have been approximately \$0.4 million lower than reported. Top line growth along with continued focus on cost containment and impacts from our operational excellence initiatives contributed to the year over year growth.

#### Corporate

Corporate costs for the three months ended July 31, 2013 increased \$1.8 million, or 20.5%, to \$10.6 million, from \$8.8 million for the three months ended July 31, 2012. The increase was primarily due to \$1.4 million in higher compensation costs.

Repositioning costs of \$0.2 million, and acquisition and integration costs of \$1.2 million in the three months ended July 31, 2013 were not included in Adjusted EBITDA.

Nine Months Ended July 31, 2013 Compared to Nine Months Ended July 31, 2012.

Edgar Filing: PATHEON INC - Form 10-Q

(in millions of U.S. dollars, except per share information)	Nine months ended July 31,			
	2013	2012	\$	%
			Change	Change
Revenues	733.1	539.1	194.0	36.0
Cost of goods sold	562.6	435.2	127.4	29.3
Gross profit	170.5	103.9	66.6	64.1
Selling, general and administrative expenses	121.6	99.0	22.6	22.8
Research and development	7.4	—	7.4	—
Repositioning expenses	11.0	6.9	4.1	59.4
Acquisition and integration costs	9.3	—	9.3	—
Impairment charge	11.3	57.9	(46.6)	(80.5)
Gain on sale of capital assets	(1.6)	—	1.6	—
Operating income (loss)	11.5	(59.9)	71.4	119.2
Interest expense, net	35.0	19.8	15.2	76.8
Foreign exchange loss, net	1.5	0.6	0.9	150.0
Refinancing expenses	29.2	—	29.2	—
Other income, net	(1.8)	(0.6)	1.2	200.0
Loss from continuing operations before income taxes	(52.4)	(79.7)	(27.3)	(34.3)
(Benefit from) provision for income taxes	(5.5)	3.6	(9.1)	(252.8)
Loss from continuing operations	(46.9)	(83.3)	(36.4)	(43.7)
Loss from discontinued operations	—	(0.2)	0.2	—
Net loss attributable to restricted voting shareholders	(46.9)	(83.5)	(36.6)	(43.8)
Basic and diluted loss per share				
From continuing operations	\$(0.337)	\$(0.643)		
From discontinued operations	—	\$(0.002)		
	\$(0.337)	\$(0.645)		
Weighted-average number of shares outstanding during period—basic (in thousands)	139,232	129,639		
Weighted-average number of shares outstanding during period—diluted (in thousands)	139,232	129,639		

Operating (Loss) Income Summary

Revenues for the nine months ended July 31, 2013 increased \$194.0 million, or 36.0%, to \$733.1 million, from \$539.1 million for the nine months ended July 31, 2012. Excluding currency fluctuations, revenues for the nine months ended July 31, 2013 would have been 35.7% higher than the nine months ended July 31, 2012. CMO revenues for the nine months ended July 31, 2013 increased \$189.3 million, or 43.2%, to \$627.4 million, from \$438.1 million for the nine months ended July 31, 2012. The increase was across most Patheon legacy sites, with the exception of Swindon and Bourgoin, and \$144.2 million of the increase was due to the Banner Acquisition. PDS revenues for the nine months ended July 31, 2013 increased \$4.7 million, or 4.7%, to \$105.7 million, from \$101.0 million for the nine months ended July 31, 2012 primarily due to stronger results across all our sites with the exception of Swindon. Excluding the impact of the Clinical Packaging business that was sold in fiscal 2012, PDS revenues grew 8.5% over the prior year. Gross profit for the nine months ended July 31, 2013 increased \$66.6 million, or 64.1%, to \$170.5 million, from \$103.9 million for the nine months ended July 31, 2012. The increase in gross profit was primarily due to higher volume and an increase in gross profit margin to 23.3% for the nine months ended July 31, 2013 from 19.3% for the nine months ended July 31, 2012. The increase in gross profit margin was driven by higher volumes and savings from our operational excellence initiatives, partially offset by increased costs of goods sold related to the fair value mark up of Banner's inventory from the acquisition of \$5.0 million, higher inventory write-offs of \$5.0 million and product returns from a packaging site of \$3.1 million. We experienced a manufacturing problem at Banner related to a change in raw materials and operational processes qualified prior to the acquisition that did not perform as expected, which led to \$3.0 million of the inventory write-offs and all the returns discussed above. Approximately \$22.8 million of the

gross margin increase over the comparable prior year period was due to the Banner Acquisition. Foreign exchange rates had a positive impact of \$1.3 million on gross profit in the nine months ended July 31, 2013 versus the same period in the prior year.

Selling, general and administrative expenses for the nine months ended July 31, 2013 increased \$22.6 million, or 22.8%, to \$121.6 million, from \$99.0 million for the nine months ended July 31, 2012. Selling, general and administrative expenses were higher as a result of Banner's selling, general and administrative costs of \$27.6 million, partially offset by lower consulting costs in the current year. Foreign exchange rates had an unfavorable impact of less than \$0.1 million on selling, general and administrative expenses in the nine months ended July 31, 2013 versus the same period in the prior year.

Research and development expenses for the nine months ended July 31, 2013 were \$7.4 million as a result of the Banner Acquisition. These expenses related to proprietary research and development efforts and consist of salaries and benefits, supplies and other costs.

Repositioning expenses for the nine months ended July 31, 2013 increased \$4.1 million, to \$11.0 million, from \$6.9 million for the same period of the prior year. Repositioning expenses for the nine months ended July 31, 2013 were associated primarily with the changes to the organizational alignment within our business as a result of the Banner Acquisition, realignment activities in our Bourgoin, France facility, and Caguas closure and consolidation, as compared to the expenses related to the Plan of Termination and Caguas closure and consolidation for the nine months ended July 31, 2012.

Acquisition and integration costs for the nine months ended July 31, 2013 were \$9.3 million. These expenses are associated with the Banner Acquisition and related integration activities. In connection with closing the acquisition on December 14, 2012, we incurred, and expect to incur, additional acquisition-related costs consisting of consultants, system and customer conversions, and other integration-related costs. These costs will be recognized as operating expenses as incurred.

We incurred an impairment charge of \$11.3 million for the nine months ended July 31, 2013 related to the planned closure of our recently acquired Olds Canada facility by the end of fiscal 2013 for \$10.1 million, and a \$1.2 million relating to two IPR&D projects that were curtailed at the Banner, High Point facility. Impairment charges for the nine months ended July 31, 2012 were \$57.9 million relating to the winding down or transferring PDS and non-cephalosporin commercial production from our Swindon, U.K. facility to other facilities.

Operating loss for the nine months ended July 31, 2013 decreased \$71.4 million to income of \$11.5 million (1.6% of revenues), from a loss of \$59.9 million (-11.1% of revenues) for the nine months ended July 31, 2012 as a result of the factors discussed above.

#### Refinancing expenses

During the nine months ended July 31, 2013, we incurred expenses of \$29.2 million in connection with our refinancing activities related to the Banner Acquisition. These costs primarily included the early redemption penalty related to the repayment of our Notes and the write-off of deferred financing costs on the Notes and the ABL (each as defined and described more fully below in "-Liquidity and Capital Resources").

#### Loss from Continuing Operations Before Income Taxes

We reported loss from continuing operations before income taxes of \$52.4 million for the nine months ended July 31, 2013, compared to a loss of \$79.7 million for the nine months ended July 31, 2012. The operating items discussed above in addition to interest and refinancing expenses were the primary drivers of the year over year variance.

#### Income Taxes

Income taxes were a benefit of \$5.5 million for the nine months ended July 31, 2013, compared to an expense of \$3.6 million for the nine months ended July 31, 2012. The increase in tax benefit was primarily driven by current benefits of approximately \$3.2 million recorded as a result of changes in tax laws and rates taking effect in 2013, releasing a valuation allowance of approximately \$0.5 million for the nine months ended July 31, 2012, recording of research and development tax credits related to calendar year 2012 of approximately \$0.4 million and a mix of income and loss from operating units and pre-tax losses in some entities for which no tax benefits were recognized in 2013.

#### Loss from Continuing Operations and Loss Per Share from Continuing Operations

We recorded loss from continuing operations for the nine months ended July 31, 2013 of \$46.9 million, compared to \$83.3 million for the nine months ended July 31, 2012. The basic and diluted loss per share from continuing operations for the nine months ended July 31, 2013 was 33.7¢ cent compared to 64.3¢ cent for the nine months ended July 31, 2012.



### Loss and Loss Per Share from Discontinued Operations

Discontinued operations for the nine months ended July 31, 2012 include the results of the Carolina, Puerto Rico operations. Financial details of the operating activities of the Carolina operations are disclosed in "Note 3—Discontinued Operations, Plant Consolidations, Sales and Asset Impairments." The loss from discontinued operations for the nine months ended July 31, 2012 was \$0.2 million, or 0.2¢ per share. These costs relate to the final wind down of the Carolina facility.

### Net Loss Attributable to Restricted Voting Shareholders and Loss Per Share

Net loss attributable to restricted voting shares for the nine months ended July 31, 2013 was \$46.9 million, or 33.7¢ per share for both basic and diluted, compared to a loss of \$83.5 million, or 64.5¢ per share, for the nine months ended July 31, 2012.

The computation of net income per share did not include 11,042,625 and 13,028,718 outstanding options in the nine months ended July 31, 2013 and 2012, respectively, because such options were anti-dilutive in nature.

The following provides certain information regarding our business segments for the nine months ended July 31, 2013 and 2012:

(in millions of U.S. dollars)	Nine months ended July 31,		\$	%
	2013	2012		
Revenues				
Commercial Manufacturing				
North America	394.1	249.1	145.0	58.2
Europe	233.3	189.0	44.3	23.4
Total Commercial Manufacturing	627.4	438.1	189.3	43.2
Pharmaceutical Development Services	105.7	101.0	4.7	4.7
Total Revenues	733.1	539.1	194.0	36.0
Adjusted EBITDA				
Commercial Manufacturing				
North America	64.3	36.2	28.1	77.6
Europe	34.8	20.5	14.3	69.8
Total Commercial Manufacturing	99.1	56.7	42.4	74.8
Pharmaceutical Development Services	27.6	19.1	8.5	44.5
Corporate EBITDA	(31.5)	(24.8)	6.7	27.0
Total Adjusted EBITDA	95.2	51.0	44.2	86.7

### Commercial Manufacturing

Total CMO revenues for the nine months ended July 31, 2013 increased \$189.3 million, or 43.2%, to \$627.4 million, from \$438.1 million for the nine months ended July 31, 2012. Had local currency exchange rates remained constant to the rates of the nine months ended July 31, 2012, CMO revenues for the Patheon legacy entities for the nine months ended July 31, 2013 would have been approximately 42.9% higher than the same period of the prior year.

Approximately \$144.2 million of the total year over year CMO growth resulted from the Banner Acquisition.

North American CMO revenues for the nine months ended July 31, 2013 increased \$145.0 million, or 58.2%, to \$394.1 million, from \$249.1 million for the nine months ended July 31, 2012. The increase was due to an increase in customer demand across all sites, with \$120.9 million of the increase resulting from the Banner Acquisition.

European CMO revenues for the nine months ended July 31, 2013 increased \$44.3 million, or 23.4%, to \$233.3 million, from \$189.0 million for the nine months ended July 31, 2012. Had European currency exchange rates remained constant to the rates of the nine months ended July 31, 2012, European CMO revenues for the Patheon legacy entities for the nine months ended July 31, 2013 would have been approximately 22.6% higher than the same period of the prior year. The increase was primarily due to increases in our Italian operations, partially offset by weakness in Swindon and Bourgoin. Approximately \$23.3 million of the year over year European CMO revenue growth resulted from the Banner Acquisition.



Total CMO Adjusted EBITDA for the nine months ended July 31, 2013 increased \$42.4 million to \$99.1 million, from \$56.7 million for the nine months ended July 31, 2012. This represents an Adjusted EBITDA margin of 15.8% for the nine months ended July 31, 2013 compared to 12.9% for the nine months ended July 31, 2012. Had local currency exchange rates and foreign exchange gains and losses remained constant to those of the nine months ended July 31, 2012, CMO Adjusted EBITDA for the nine months ended July 31, 2013 would have been approximately \$0.7 million higher. The Adjusted EBITDA increase was driven by higher volumes and improved margins driven by our operational excellence initiatives, partially offset by inventory write-offs of \$5.0 million and higher foreign exchange losses of \$0.7 million. Included in the CMO Adjusted EBITDA was a \$9.4 million impact from Banner. Total CMO Adjusted EBITDA for the nine months ended July 31, 2013 did not include \$11.3 million of impairment charges related to the closure of the Banner facility in Canada and closed IP R&D projects, \$5.0 million of higher cost of goods sold related to amortization of the fair value mark-up of Banner's inventory from the acquisition, and product returns from a packaging site and inventory write-offs totaling \$6.1 million related to a manufacturing problem at Banner resulting from a change in raw materials and operational processes qualified prior to the acquisition that did not perform as expected. Repositioning costs of \$7.0 million in the nine months ended July 31, 2013 were not included in Adjusted EBITDA.

North American Adjusted EBITDA for the nine months ended July 31, 2013 increased \$28.1 million, to \$64.3 million, from \$36.2 million for the nine months ended July 31, 2012. The increase was primarily driven by higher volumes and margins as a result of our operational excellence initiatives, partially offset by higher inventory write-offs of \$5.5 million. Included in the North American Adjusted EBITDA was a \$7.1 impact from Banner.

European Adjusted EBITDA for the nine months ended July 31, 2013 increased \$14.3 million, to \$34.8 million, from \$20.5 million for the nine months ended July 31, 2012. Had European currency exchange rates remained constant to those of the nine months ended July 31, 2012, European CMO Adjusted EBITDA for the nine months ended July 31, 2013 would have been approximately \$1.9 million higher. The increase was primarily driven by higher volumes and margins as a result of our operational excellence initiatives, partially offset by foreign exchange loss of \$1.3 million. Included in the European Adjusted EBITDA was a positive \$2.2 million impact from Banner.

#### Pharmaceutical Development Services

Total PDS revenues for the nine months ended July 31, 2013 increased by \$4.7 million, or 4.7%, to \$105.7 million, from \$101.0 million for the nine months ended July 31, 2012. Had the local currency exchange rates remained constant to the nine months ended July 31, 2012, PDS revenues for the nine months ended July 31, 2013 would have been 4.6% higher than the same period of the prior year. Excluding the impact of the Clinical Packaging business that was sold in fiscal 2012, the PDS revenues grew by 8.5% over the same period of prior year. Higher development activities from new contracts across most sites contributed to the improved performance.

Total PDS Adjusted EBITDA for the nine months ended July 31, 2013 increased \$8.5 million, or 44.5%, to \$27.6 million, from \$19.1 million for the nine months ended July 31, 2012. Had local currency exchange rates remained constant to those of the nine months ended July 31, 2012, PDS Adjusted EBITDA for the nine months ended July 31, 2013 would have been approximately \$0.5 million lower than reported. Higher revenue, positive impact from our operational excellence initiatives, and cost controls contributed to the year over year growth. Repositioning costs of \$0.3 million in the nine months ended July 31, 2013 were not included in Adjusted EBITDA.

#### Corporate

Corporate costs for the nine months ended July 31, 2013 increased \$6.7 million, or 27.0%, to \$31.5 million, from \$24.8 million for the nine months ended July 31, 2012. Higher professional fees of \$3.3 million, higher marketing and travel costs along with \$1.8 million in Banner general and administrative costs contributed to the year over year increase.

Refinancing costs of \$29.2 million, repositioning costs of \$3.7 million, and acquisition and integration costs of \$9.3 million in the nine months ended July 31, 2013 were not included in Adjusted EBITDA.

#### Liquidity and Capital Resources

##### Overview



Cash and cash equivalents totaled \$40.9 million at July 31, 2013 and \$39.4 million at October 31, 2012. Our total debt was \$610.4 million at July 31, 2013 and \$313.1 million at October 31, 2012.

Our primary source of liquidity is cash flow from operations and borrowings under our credit arrangements. Our principal uses of cash have been for operating expenditures, capital expenditures, repositioning expenditures, debt servicing

Table of Contents

requirements, integration costs associated with the Banner Acquisition and employee benefit obligations. We expect cash flow from operations, cash on hand and borrowing under our current revolver to be sufficient to fund our existing level of operating expenses, capital expenditures, and interest expense for at least the next 12 months.

From time to time, we evaluate strategic opportunities, including potential acquisitions, divestitures or investments in complementary businesses, and we anticipate continuing to make such evaluations. We may also access capital markets through the issuance of debt or equity securities in connection with the acquisition of complementary businesses or other significant assets or for other strategic opportunities.

If our cash flow is not sufficient to service our debt and adequately fund our business, we may be required to seek further additional financing or refinancing or dispose of assets. We may not be able to effect any of these alternatives on satisfactory terms or at all. In addition, our financial leverage could adversely affect our ability to raise additional capital to fund our operations, could impair our ability to respond to operational challenges, changing business and economic conditions and new business opportunities and may make us vulnerable in the event of a downturn in our business.

**Summary of Cash Flows**

The following table summarizes our cash flows for the periods indicated:

	Nine months ended July 31,	
	2013	2012
(in millions of U.S. dollars)	\$	\$
Cash (used in) provided by operating activities of continuing operations	(25.6 )	7.2
Cash used in operating activities of discontinued operations	(0.1 )	(0.4 )
Cash (used in) provided by operating activities	(25.7 )	6.8
Cash used in investing activities	(283.7 )	(32.7 )
Cash provided by financing activities	308.3	30.3
Other	2.6	(2.4 )
Net increase in cash and cash equivalents during the period	1.5	2.0

**Cash Used in Operating Activities**

Cash used in operating activities from continuing operations for the nine months ended July 31, 2013 decreased \$32.8 million, to a usage of \$25.6 million, from a cash source of \$7.2 million for the nine months ended July 31, 2012. The unfavorable year over year change was driven primarily by changes in deferred revenue, working capital requirements and higher interest payment associated with the new debt.

**Cash Used in Investing Activities**

The following table summarizes the cash used in investing activities for the periods indicated:

	Nine months ended July 31,	
	2013	2012
(in millions of U.S. dollars)	\$	\$
Cash used in investing activities	(283.7 )	(32.7 )

Cash used in investing activities from continuing operations for the nine months ended July 31, 2013 increased \$250.9 million, to \$283.7 million, from \$32.8 million for the nine months ended July 31, 2012 primarily due to the Banner Acquisition. The \$32.7 million in fiscal 2012 was primarily project-related capital expenditures, which compares to \$34.2 million for the nine months ended July 31, 2013.

Our principal ongoing investment activities are project-related and sustaining capital programs at our network of sites. The majority of our capital allocation is normally invested in project-related programs, which are defined as outlays that will generate growth in capacity and revenues, while sustaining expenditures related to the preservation of

existing assets and capacity.

Cash Provided by Financing Activities

The following table summarizes the cash used in financing activities for the periods indicated:

40

---

Table of Contents

	Nine months ended July	
	31,	2012
	2013	2012
(in millions of U.S. dollars)	\$	\$
Decrease in short-term borrowings	—	(1.3 )
Proceeds from long-term borrowings	633.8	35.5
Increase in deferred financing costs	(22.7 )	—
Repayment of debt, net of penalty payment	(337.8 )	(3.9 )
Share issuance costs	(0.8 )	—
Proceeds on issuance of restricted voting shares	35.8	—
Cash provided by financing activities	308.3	30.3

Cash provided by financing activities for the nine months ended July 31, 2013 was \$308.3 million compared \$30.3 million for the nine months ended July 31, 2012. This increase of cash inflow is due to the refinancing activities during the nine months ended July 31, 2013, which resulted from the funding requirements related to the Banner Acquisition.

## Financing Arrangements

## Current Credit Arrangements - \$660 Million Credit Facility

On December 14, 2012, in connection with the Banner Acquisition, we entered into a credit agreement that provides for the Credit Facility, which is comprised of Secured Term Loan in the amount of \$575.0 million and the Secured Revolving Facility of up to \$85.0 million (the "Credit Agreement"). Up to \$30.0 million of the Secured Revolving Facility is available for letters of credit. The Secured Term Loan matures on December 14, 2018, and the Secured Revolving Facility matures on December 14, 2017. The Secured Term Loan bears interest at a rate per annum equal to, at our option, LIBOR plus 6.00%, with a LIBOR "floor" of 1.25%, or an alternate base rate plus 5.00%, with an alternate base rate "floor" of 2.25%. Borrowings under the Secured Revolving Facility bear interest for eurodollar loans at Libor plus 5.50% and base rate loans at the base rate plus 4.50%. We will also pay a commitment fee of 0.50% per annum on the unused portion of the Secured Revolving Facility with a step down to 0.375% when the First Lien Leverage Ratio (as defined in the Credit Agreement) is less than or equal to 3.00 to 1.00.

First Lien Leverage Ratio is generally defined in the Credit Agreement as the ratio of (i) the sum of the aggregate principal amount of the Company's and its restricted subsidiaries' indebtedness for borrowed money, principal amount of capital lease obligations and debt obligations evidenced by promissory notes or similar instruments plus the unrestricted cash of the Company and its restricted subsidiaries, in each case as set forth in the Credit Agreement, to (ii) Consolidated EBITDA. Consolidated EBITDA is generally defined in the Credit Agreement as income (loss) from continuing operations before repositioning expenses, interest expense, foreign exchange losses reclassified from other comprehensive income (loss), refinancing expenses, acquisition-related costs, gains and losses on sale of capital assets, income taxes, asset impairment charges, depreciation and amortization, stock-based compensation expense, consulting costs related to the Company's operational initiatives, purchase accounting adjustments, other income and expenses, non-cash charges, expenses related to the Banner Acquisition, pro forma cost savings from operational excellence initiatives and plant consolidations, pro forma synergies from the Banner Acquisition, and proceeds from business interruption insurance, among other adjustments. Consolidated EBITDA is not equivalent to Adjusted EBITDA disclosed elsewhere in this quarterly report on Form 10-Q.

We are required to make the following mandatory prepayments in respect of the Secured Term Loan: (i) 50% of Excess Cash Flow (as defined in the Credit Agreement) when we maintain a First Lien Leverage Ratio of greater than 3.50 to 1.00, with step downs to (a) 25% when we maintain a First Lien Leverage Ratio of less than or equal to 3.50 to 1.00,

1.00 but greater than 3.00 to 1.00 and (b) 0% when we maintain a First Lien Leverage Ratio of less than or equal to 3.00 to 1.00; (ii) 100% of the net cash proceeds of certain asset sales (including insurance and condemnation proceeds), subject to thresholds, reinvestment rights and certain other exceptions; and (iii) 100% of the net cash proceeds of issuances of debt obligations, subject to certain exceptions and thresholds. In the event the Secured Term Loan is prepaid, refinanced, substituted or replaced (including by way of amendment) in whole or in part prior to December 14, 2013 concurrently with the incurrence of indebtedness similar to the Secured Term Loan with a lower all-in yield than that of the Secured Term Loan, any amounts so prepaid, refinanced, substituted or replaced will be subject to a prepayment fee of 1.00%. Excess Cash Flow is generally defined in the Credit Agreement as Consolidated EBITDA (as defined in the Credit Agreement) plus, without duplication, (i) decreases in working capital, (ii) extraordinary or nonrecurring income or gains and (iii) certain other adjustments, minus,

Table of Contents

without duplication, (a) interest, (b) taxes, (c) increases in working capital, (d) capital expenditures paid in cash and (e) certain other adjustments, in each case as set forth in the Credit Agreement.

Under the Credit Agreement, we are required to maintain a First Lien Leverage Ratio below a certain amount for each Testing Period, defined as a single period consisting of the most recent four consecutive fiscal quarters ending on the covenant determination date. The following table discloses the maximum permitted First Lien Leverage Ratios permitted under the Credit Agreement:

Testing Period Ending	Maximum Ratio
April 30, 2013 through July 31, 2014	5.50 to 1.00
October 31, 2014 through July 31, 2015	5.00 to 1.00
October 31, 2015 through April 30, 2016	4.75 to 1.00
July 31, 2016 through October 31, 2016	4.50 to 1.00
January 31, 2017 and thereafter	4.25 to 1.00

The Credit Agreement also (i) required us to make a number of representations and warranties, including representations and warranties regarding our legal status and our business, and (ii) subjects us to a number of affirmative covenants, including requirements to deliver certain information to the lenders, maintain insurance and comply with laws, in each case subject to certain exceptions as set forth in the Credit Agreement.

The Credit Agreement also subjects us to a number of negative covenants that restrict our ability and the ability of our subsidiaries to, among other things:

- incur additional indebtedness;
- issue additional equity;
- pay dividends on or make distributions in respect of capital stock or make certain other restricted payments or investments;
- enter into agreements that restrict distributions from subsidiaries or restrict our ability to incur liens on certain of our assets;
- make capital expenditures;
- sell or otherwise dispose of assets, including capital stock of subsidiaries;
- enter into transactions with affiliates;
- change our line of business
- create or incur liens;
- change our fiscal year; and
- merge or consolidate.

The Credit Agreement contains a number of events of default, including, among others:

- failure to make payments when due;
- breaches of representations and warranties;
- breaches of covenants;
- defaults under other indebtedness (cross-defaults);
- invalidity of security documents;
- judgments in excess of a specified amount;
- bankruptcy or insolvency;
- ERISA events and similar events under non-U.S. plans; and
- a change of control.

Our failure to maintain the required First Lien Leverage Ratio or our breach of the other covenants and requirements contained in the Credit Agreement could result in an event of default, which may allow our lenders to accelerate our

debt and may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. As of July 31, 2013, we were in compliance with the covenants and other requirements in the Credit Agreement.

The Credit Facility is guaranteed by certain of our wholly-owned subsidiaries and secured by a first priority pledge on substantially all of our assets and the subsidiary guarantors, in each case subject to certain exceptions.

Table of Contents

Consolidated EBITDA is based on the definition in the Credit Agreement, is not defined under U.S. GAAP and is subject to important limitations. We have included the calculation of Consolidated EBITDA for the period presented below as Consolidated EBITDA is a component of certain covenants under the Credit Agreement. Because not all companies use identical calculations, our presentation of Consolidated EBITDA may not be comparable to other similarly titled measures of other companies.

Our Consolidated EBITDA for the last four fiscal quarters ended July 31, 2013 based on the definition in our Credit Agreement is calculated as follows:

	Last twelve months ended July 31, 2013	
(in millions of U.S. dollars)	\$	
Consolidated EBITDA per Credit Agreement	187.7	
Less:		
Acquired EBITDA of Banner	(4.9	)
Pro forma cost savings	(45.8	)
Other	(5.3	)
Adjusted EBITDA	131.7	
(Deduct) add:		
Depreciation and amortization	(45.7	)
Repositioning expenses	(10.2	)
Acquisition and integration costs	(18.6	)
Interest expense, net	(41.7	)
Asset Impairment charges	(11.3	)
Gain on sale of capital assets	1.2	
Provision for income taxes	(34.3	)
Refinancing expenses	(29.2	)
Operational initiatives related consulting costs	(2.3	)
Acquisition-related litigation expenses	(4.0	)
Stock-based compensation expense	(3.0	)
Purchase accounting adjustments	(5.0	)
Other	2.4	
Loss from continuing operations	(70.0	)
Add (deduct):		
Depreciation and amortization	45.7	
Impairment charge	11.3	
Stock-based compensation	3.0	
Net change in non-cash working capital	(19.2	)
Net change in deferred revenues	(0.2	)
Non-cash interest	8.5	
Other, primarily changes in long-term assets and liabilities	21.4	
Cash flows from operating activities	0.5	
Cash flows from investing activities	(302.9	)
Cash flows from financing activities	304.3	



Included in our pro forma cost savings are the estimated impact of our operational excellence initiatives, plant consolidation savings, and other synergies related to the Banner Acquisition, assuming such activities were completed as of August 1, 2012.

Our net debt calculation for our credit facility as of July 31, 2013, is as follows:

43

---

Table of Contents

(in millions of U.S. dollars)	\$
Total funded debt	597.2
Less: cash and cash equivalents	(35.0 )
Net debt	562.2

As part of the Credit Agreement, we are required to maintain a leverage ratio below a certain threshold. Our leverage ratio is calculated by dividing our total net debt at the end of the applicable fiscal quarter divided by our Consolidated EBITDA for the previous 12 months. Effective for the 12-month period beginning April 30, 2013, we are required to keep our leverage ratio below 5.50. As of July 31, 2013, our leverage ratio was 2.99.

**Historical Credit Arrangements-\$280.0 Million Senior Secured Notes and \$75.0 Million Amended ABL**

In April 2010, we issued the Notes in an aggregate principal amount of \$280.0 million. We used the net proceeds of the offering to repay all of the outstanding indebtedness under our then-existing senior secured term loan and the ABL, to repay certain other indebtedness and to pay related fees and expenses. We used the remaining proceeds for general corporate purposes.

We also amended and restated the ABL in connection with the Notes offering to, among other things, extend the maturity date of this facility to April 23, 2014.

The Notes and the ABL were secured by substantially all of our assets and were guaranteed by, and secured by substantially all of the assets of, our subsidiaries in the United States (including Puerto Rico), Canada, the United Kingdom (except Patheon UK Pension Trustees Limited) and The Netherlands. The Notes and the ABL were guaranteed on a limited basis by, and secured by certain assets of, our subsidiaries in France, Italy and Switzerland.

As part of the Refinancing, effective December 14, 2012, we terminated all commitments and repaid all amounts owed under the ABL. On December 14, 2012, as part of the previously announced tender offer for the Notes, we paid or deposited with an escrow agent an aggregate of approximately \$307.2 million in order to purchase all outstanding Notes. As a result, we were released from our obligations under the Notes and the indenture governing the Notes pursuant to the satisfaction and discharge provisions of such indenture.

**Financing Ratios**

Total interest-bearing debt at July 31, 2013 was \$610.4 million, \$297.3 million higher than at October 31, 2012. At July 31, 2013, our consolidated ratio of interest-bearing debt to shareholders' equity was 535.9%, compared to 251.9% at October 31, 2012.

**Off-Balance Sheet Arrangements**

We do not use off-balance sheet arrangements to structure any of our financial arrangements. We do not have any interests in unconsolidated special-purpose or structured finance entities.

**Tabular Disclosure of Contractual Obligations**

The following reflects the impact of our new Credit Facilities on our contractual obligations:

(in millions of U.S. dollars)	Long-term debt obligation as of July 31, 2013 (1)				
	Total	Year 1	2-3 Years	4-5 Years	After 5 Years
	\$	\$	\$	\$	\$
Long-term debt	621.1	6.9	13.6	56.1	544.5
Interest on long-term debt (2)	227.2	43.7	86.1	82.9	14.5
Total long-term debt obligations	848.3	50.6	99.7	139.0	559.0

(1) The amounts displayed in the chart relate only to our long-term debt. For information relating to all of our outstanding contractual obligations, please see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations-Tabular Disclosure of Contractual Obligations." contained in our 2012 Annual Report on Form 10-K.

(2) Represents interest payments under our Credit Facility based on the applicable interest rates in effect on July 31, 2013.



## Table of Contents

### Recent Accounting Pronouncements

See "Note 1—Accounting policies—Recently issued accounting pronouncements" to our unaudited consolidated financial statements contained in this quarterly report on Form 10-Q for a description of recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our consolidated financial statements.

### Critical Accounting Estimates

For information regarding our critical accounting policies and estimates, please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Estimates" contained in our 2012 Form 10-K. There have been no material changes to the critical accounting policies previously disclosed in that report, except as discussed below.

### Goodwill

As a result of the Banner Acquisition, we recorded goodwill representing the excess of the purchase price over the fair value of the assets acquired and liabilities assumed. We test goodwill for impairment at least annually in the fiscal fourth quarter, or when indications of potential impairment exist. We monitor for the existence of potential impairment indicators throughout the fiscal year. Testing is performed with respect to each of our reporting units that have been allocated goodwill, which we have determined are the sites within our CMO segment.

We may initiate goodwill impairment testing by considering qualitative factors to determine whether it is more likely than not that a reporting unit's carrying value is greater than its fair value. Such factors may include the following, among others: a significant decline in the reporting unit's expected future cash flows; a sustained, significant decline in our stock price and market capitalization; a significant adverse change in legal factors or in the business climate, unanticipated competition; and slower growth rates; and changes in management, key personnel, strategy or customers. If our qualitative assessment reveals that goodwill impairment is more likely than not, we perform the two-step impairment test. Alternatively, we may bypass the qualitative test and initiate goodwill impairment testing with the first step of the two-step goodwill impairment test.

During the first step of the goodwill impairment test, we compare the fair value of the reporting unit to its carrying value, including goodwill. Determining the fair value of the reporting unit entails significant estimates and assumptions including, but not limited to, developing appropriate discount rates and estimating future cash flows from the reporting units products or services. If the fair value of a reporting unit exceeds its carrying value, then we conclude that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, we perform the second step of the goodwill impairment test to measure possible goodwill impairment loss. During the second step, we hypothetically value the reporting unit's tangible and intangible assets and liabilities as if the reporting unit had been acquired in a business combination. We then compare the implied fair value of the reporting unit's goodwill to the carrying value of its goodwill. If the carrying value of the reporting unit's goodwill exceeds the implied fair value of the goodwill, we recognize an impairment loss in an amount equal to the excess, not to exceed the carrying value of the reporting unit's goodwill. Once an impairment loss is recognized, the adjusted carrying value of the goodwill becomes the new accounting basis of the goodwill for the segment. Due to uncertain market conditions and potential changes in our strategy, product and service portfolio or reporting units, it is possible that the forecasts we use to support goodwill could change in the future, which could result in goodwill impairment charges that would adversely affect our results of operations.

### Intangible Assets

As a result of the Banner Acquisition, we recorded various intangible assets, including technology, in process research and development, customer relationships and trade name. We will test for definite lived intangible assets whenever events or changes in circumstances indicate that the carrying amount will not be recoverable. If such indicators are present, we assesses the recoverability of the intangible assets by determining whether the carrying value of such assets can be recovered through undiscounted future cash flows. If the sum of the undiscounted cash flows is less than

the carrying amount, the excess of the carrying amount over the estimated fair value, based on the discounted cash flows, is recorded as a charge to earnings.

For indefinite-lived intangible assets other than goodwill, we compare the fair value of the intangible asset with the asset's carrying amount. If the fair value is less than the carrying amount, we will recognize an impairment. This impairment test for indefinite-lived intangible assets other than goodwill is conducted annually, concurrently with the goodwill test.

#### Seasonality

Seasonality influences our revenues as some of our CMO and PDS operations have traditionally been lower in our first fiscal quarter. We attribute this trend to several factors, including (i) the reassessment by many customers of their need for

Table of Contents

additional product in the last quarter of the calendar year in order to use existing inventories of products; (ii) the lower production of seasonal cough and cold remedies in the first fiscal quarter; (iii) limited project activity towards the end of the calendar year by many small pharmaceutical and biotechnology customers involved in PDS projects in order to reassess progress on their projects and manage cash resources; and (iv) the Patheon-wide facility shutdown during a portion of the traditional holiday period in December and January.

**Forward-Looking Statements**

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which reflect our expectations regarding our future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. All statements, other than statements of historical fact, are forward-looking statements. Wherever possible, words such as "plans," "expects," or "does not expect," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "should," "would," "might" or "will" be taken, occur or be achieved have been used to identify these forward-looking statements. Although the forward-looking statements contained in this quarterly report on Form 10-Q reflect our current assumptions based upon information currently available to us and based upon what we believe to be reasonable assumptions, we cannot be certain that actual results will be consistent with these forward-looking statements. Our current material assumptions include assumptions related to customer volumes, regulatory compliance, foreign exchange rates, employee severance costs associated with termination and projected integration savings related to the Banner Acquisition. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause our actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to international operations and foreign currency fluctuations; customer demand for our services; regulatory matters affecting manufacturing and pharmaceutical development services; impacts of acquisitions, divestitures and restructurings, including our ability to achieve our intended objectives with respect to such transactions and integrate businesses that we may acquire; implementation of our new corporate strategy; our ability to effectively transfer business between facilities; the global economic environment; our exposure to complex production issues; our substantial financial leverage; interest rate risks; potential environmental, health and safety liabilities; credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; the existence of a significant shareholder; supply arrangements; pension plans; derivative financial instruments; and our dependence upon key management, scientific and technical personnel. These and other risks are described in greater detail in "Part 1-Item 1A. Risk Factors" of our 2012 Form 10-K. Although we have attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. These forward-looking statements are made as of the date of this quarterly report on Form 10-Q, and except as required by law, we assume no obligation to update or revise them to reflect new events or circumstances.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk****Foreign Currency Risk**

Our business is conducted in several currencies—Canadian dollars and U.S. dollars for our Canadian operations, U.S. dollars for our U.S. operations, Euros, U. S. dollars and British Sterling for our European operations and the Mexican Peso for our Mexican operations. We are subject to foreign currency transaction risk because a significant portion of our revenues and operating expenses from our operations in certain countries are denominated in different currencies. Our material foreign currency transaction risk arises from our Canadian operations. Our Canadian operations negotiate sales contracts for payment in both U.S. and Canadian dollars, and materials and equipment are

purchased in both U.S. and Canadian dollars. The majority of the non-material costs (including payroll, facilities' costs and costs of locally sourced supplies and inventory) of our Canadian operations are denominated in Canadian dollars. In the nine months ended July 31, 2013, approximately 90% of the revenues and 10% of the operating expenses of our Canadian operations were transacted in U.S. dollars. As a result, if we do not effectively hedge such foreign currency exposure, our results of operations will be adversely affected by an increase in the value of the Canadian dollar relative to such foreign currency. In addition, we may experience hedging and transactional gains or losses because of volatility in the exchange rate between the Canadian dollar and the U.S. dollar. Based on our current U.S. denominated net inflows, for each 10% change in the Canadian-U.S. dollar exchange rate, the annual impact on pre-tax income, excluding any hedging activities, would be approximately \$4.8 million. To mitigate exchange-rate risk, we utilize foreign exchange forward contracts and collars in certain circumstances to lock in exchange rates with the objective that the gain or loss on the forward contracts and collars will approximately offset the loss

Table of Contents

or gain that results from the transaction or transactions being hedged. As of July 31, 2013, we had entered into 78 foreign exchange forward contracts and collars covering approximately 80% of our Canadian-U.S. dollar cash flow exposures for fiscal 2013 and had one foreign exchange forward contract covering our Euro-U.S. dollar cash flow. See "Note 11—Financial instruments and risk management" to our unaudited consolidated financial statements. We do not hedge any of our other foreign exchange exposures. Our foreign exchange forward contracts and collars mature at various dates through April 2015 and have an aggregate fair value of \$133.4 million. As of July 31, 2013, an adverse exchange rate movement of 10% against our foreign exchange forward contracts and collars would result in a pre-tax loss of approximately \$13.3 million.

Interest Rate Risk

As of July 31, 2013, our long-term debt consisted of the Secured Term Loan and our Secured Revolving Facility, both of which bear interest at a variable rate. As of July 31, 2013, we had borrowed \$42.3 million under our Secured Revolving Facility. Assuming a 100 basis point increase in applicable interest rates, annual interest expense on our Secured Revolving Facility would (assuming a fully drawn facility) increase by approximately \$0.85 million and annual interest expense on our Secured Term Loan would increase by approximately \$5.75 million.

Item 4. Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this quarterly report on Form 10-Q, our disclosure controls and procedures are effective in that they provide reasonable assurances that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. On December 14, 2012, the Company completed the Banner Acquisition for a purchase price of \$269.0 million, of which \$117.0 million represented goodwill and identifiable intangible assets. Banner's operations contributed approximately \$144.2 million in revenues to our consolidated financial results for the nine months ended July 31, 2013. We continue to evaluate the internal control over financial reporting of the acquired business. As permitted by SEC Staff interpretive guidance for newly acquired businesses, the internal control over financial reporting of Banner was excluded from a formal evaluation of the effectiveness of our disclosure controls and procedures as of July 31, 2013.

There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the third quarter of fiscal 2013 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We will continue to evaluate the effectiveness of our disclosure controls and procedures and internal control over financial reporting on an ongoing basis and will take action as appropriate.



Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

On December 10, 2012, Procaps S.A. (“Procaps”) filed a complaint against us in the United States District Court for the Southern District of Florida (Case No. 12-cv-24356-DLG). The complaint involves our collaboration agreement with Procaps, pursuant to which both companies agreed to work together with respect to the marketing of a line of certain prescription pharmaceutical soft-gel development and manufacturing services. Procaps alleges that our acquisition of Banner, a business that historically has generated less than 10% of its revenues from softgel services for prescription pharmaceuticals, transformed the collaboration agreement into an anticompetitive restraint of trade and an agreement between direct competitors to set prices, divide markets and/or allocate geographic territories. Procaps seeks (i) a declaratory judgment that the collaboration agreement must cease and/or terminate; (ii) an injunction requiring that we divest all of Banner's soft-gel manufacturing capabilities; and (iii) monetary damages under federal and state antitrust and unfair competition laws, including treble damages for violations of the Sherman Act. We subsequently answered Procaps' complaint and filed our affirmative defenses to the complaint. On May 15, 2013, Procaps served its supplemental initial disclosures pleading damages. The parties are currently conducting discovery and trial is scheduled to commence in June 2014.

We deny all allegations contained in Procaps' complaint and believe that Procaps' claims are without merit. We intend to vigorously defend ourselves in this lawsuit. Based on our knowledge as of the date of this filing, we believe that the eventual resolution of the above matter is unlikely to have a material effect on our financial position, operating results or liquidity. However, the results of litigation are inherently unpredictable and the possibility exists that the ultimate resolution of the matters could result in a material adverse effect on our business, results of operations and financial condition.

Item 1A. Risk Factors

There have been no material changes in the risk factors described in Item 1A of our 2012 Form 10-K.

Item 6. Exhibits

The exhibits listed in the accompanying exhibit index are filed as part of this quarterly report on Form 10-Q, and such exhibit index is incorporated by reference herein.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: September 5, 2013

PATHEON INC.

By: /s/ JAMES C. MULLEN  
James C. Mullen  
Chief Executive Officer

By: /s/ STUART GRANT  
Stuart Grant  
Executive Vice President, Chief Financial Officer

Table of Contents

## EXHIBIT INDEX

Exhibit Number	Description of Document	Incorporated by Reference			Filed Herewith
		Form	Filing Date	Number	
10.1	Separation Agreement between Patheon Italia S.p.A. and Antonella Mancuso dated July 26, 2013.				X
31.1	Certification by Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
31.2	Certification by Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
32.2	Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
101*	The following materials from Patheon Inc.'s Quarterly Report on Form 10-Q for the quarter ended July 31, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) Unaudited Consolidated Statements of Comprehensive Income (Loss); (iv) the Unaudited Consolidated Statement of Changes in Shareholders' Equity; (v) the Unaudited Consolidated Statements of Cash Flows and (vi) the Notes to Unaudited Consolidated Financial Statements.				X

\* Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.